

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT

Winrevair 45 mg powder and solvent for solution for injection

Winrevair 60 mg powder and solvent for solution for injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Winrevair 45 mg powder and solvent for solution for injection

Each vial contains 45 mg of sotatercept. After reconstitution, each mL of solution contains 50 mg sotatercept.

Winrevair 60 mg powder and solvent for solution for injection

Each vial contains 60 mg of sotatercept. After reconstitution, each mL of solution contains 50 mg sotatercept.

Sotatercept is a recombinant homodimeric fusion protein consisting of the extracellular domain of human activin receptor type IIA (ActRIIA) linked to the Fc domain of human IgG1, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Powder and solvent for solution for injection (powder for injection).

Powder: white to off-white powder.

Solvent: clear colourless water for injections.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Winrevair, in combination with other pulmonary arterial hypertension (PAH) therapies, is indicated for the treatment of PAH in adult patients with WHO Functional Class (FC) II, III, and IV (see section 5.1).

4.2 Posology and method of administration

Winrevair treatment should only be initiated and monitored by a physician experienced in the diagnosis and treatment of PAH.

Posology

Winrevair is administered once every 3 weeks as a single subcutaneous injection according to patient weight.

Recommended starting dose

Haemoglobin (Hgb) and platelet count should be obtained prior to the first dose (see section 4.4). Initiation of treatment is contraindicated if platelet count is consistently $< 50 \times 10^9/L$ (see section 4.3).

Treatment is initiated with a single dose of 0.3 mg/kg (see Table 1).

Table 1: Injection volume for dose of 0.3 mg/kg

Patient weight range (kg)	Injection volume (mL)*	Kit type
30.0 – 40.8	0.2	Kit containing 1 x 45 mg vial
40.9 – 57.4	0.3	
57.5 – 74.1	0.4	
74.2 – 90.8	0.5	
90.9 – 107.4	0.6	
107.5 – 124.1	0.7	
124.2 – 140.8	0.8	
140.9 – 157.4	0.9	Kit containing 1 x 60 mg vial
157.5 – 174.1	1.0	
174.2 – 180.0	1.1	

*The concentration of the reconstituted solution is 50 mg/mL (see section 6.6)

Recommended target dose

Three weeks after a single starting dose of 0.3 mg/kg, the dose should be escalated to the recommended target dose of 0.7 mg/kg after verifying acceptable Hgb and platelet count (see section 4.2 “Dose adjustments due to increase in haemoglobin or decreased platelet count”). Treatment should be continued at 0.7 mg/kg every 3 weeks unless dose adjustments are required.

Table 2: Injection volume for dose of 0.7 mg/kg

Patient weight range (kg)	Injection volume (mL)*	Kit type
30.0 – 31.7	0.4	Kit containing 1 x 45 mg vial
31.8 – 38.9	0.5	
39.0 – 46.0	0.6	
46.1 – 53.2	0.7	
53.3 – 60.3	0.8	
60.4 – 67.4	0.9	
67.5 – 74.6	1.0	Kit containing 1 x 60 mg vial
74.7 – 81.7	1.1	
81.8 – 88.9	1.2	
89.0 – 96.0	1.3	Kit containing 2 x 45 mg vials
96.1 – 103.2	1.4	
103.3 – 110.3	1.5	
110.4 – 117.4	1.6	
117.5 – 124.6	1.7	
124.7 – 131.7	1.8	
131.8 – 138.9	1.9	Kit containing 2 x 60 mg vials
139.0 – 146.0	2.0	
146.1 – 153.2	2.1	
153.3 – 160.3	2.2	
160.4 – 167.4	2.3	
167.5 and above	2.4	

*The concentration of the reconstituted solution is 50 mg/mL (see section 6.6)

Dose adjustments due to increase in haemoglobin or decreased platelet count

Hgb and platelet count should be monitored for the first 5 doses, or longer if values are unstable. Thereafter, Hgb and platelet count should be verified every 3 to 6 months and the dose adjusted if necessary (see sections 4.4 and 4.8).

Treatment should be delayed for 3 weeks (i.e., one dose delay) if any of the following occur:

- Hgb increases > 1.24 mmol/L (2 g/dL) from the previous dose and is above the upper limit of normal (ULN).
- Hgb increases > 2.48 mmol/L (4 g/dL) from baseline.
- Hgb increases > 1.24 mmol/L (2 g/dL) above ULN.
- Platelet count decreases $< 50 \times 10^9/L$.

Hgb and platelet count should be obtained again before reinitiating treatment.

For treatment delays lasting > 9 weeks, treatment should be restarted at 0.3 mg/kg, and the dose should be escalated to 0.7 mg/kg after verifying acceptable Hgb and platelet count.

For treatment delays lasting > 9 weeks due to platelet counts consistently $< 50 \times 10^9/L$, the physician should carry out a benefit/risk re-evaluation for the patient before reinitiating treatment.

Missed dose

If a dose is missed, administer as soon as possible. If the missed dose is not taken within 3 days of the scheduled date, adjust the schedule to maintain 3-week dosing intervals.

Elderly

No dose adjustment is required in elderly patients ≥ 65 years old (see section 5.2).

Renal impairment

No dose adjustment is required based on renal impairment (see section 5.2). Limited data are available on the use of sotatercept in PAH patients with severe renal impairment (estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m²).

Hepatic impairment

No dose adjustment is required based on hepatic impairment (Child-Pugh Classification A to C). Sotatercept has not been studied in patients with hepatic impairment (see section 5.2).

Paediatric population

The safety and efficacy of Winrevair in children and adolescents below 18 years of age have not yet been established. No data are available.

Method of administration

Winrevair is for single use only.

It should be reconstituted before use. The reconstituted medicinal product is a clear to opalescent and colourless to slightly brownish-yellow solution.

Winrevair should be administered by subcutaneous injection in the abdomen (at least 5 cm away from navel), upper arm, or upper thigh. It should not be injected into sites that are scarred, tender, or bruised. The same injection site should not be used on two consecutive injections.

Winrevair powder and solvent for solution for injection is intended for use under the guidance of a healthcare professional (HCP). Patients and caregivers may administer the medicinal product when considered appropriate and when they receive training from a HCP in how to reconstitute, prepare, measure and inject Winrevair powder and solvent for solution for injection. A HCP should confirm at a subsequent visit, soon after training, that the patient or caregiver can perform these steps correctly. A HCP should also consider reconfirming the patient's or caregiver's administration technique if the

dose is adjusted, if the patient requires a different kit, if the patient develops erythrocytosis (see section 4.4), or at any time at the discretion of the HCP.

Refer to section 6.6 for detailed instructions on the proper preparation and administration of Winrevair.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Patients with platelet counts consistently $< 50 \times 10^9/L$ before initiating treatment.

4.4 Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Erythrocytosis

Increases in Hgb have been observed in patients during treatment with sotatercept. Severe erythrocytosis may increase the risk of thromboembolic events and hyperviscosity syndrome. Use caution in patients with erythrocytosis who are at increased risk of thromboembolic events. Hgb should be monitored before each dose for the first 5 doses, or longer if values are unstable, and every 3 to 6 months thereafter to determine if dose adjustments are required (see sections 4.2 and 4.8). If a patient develops erythrocytosis, HCP should consider re-evaluating the patient's or caregiver's administration technique.

Severe thrombocytopenia

Decreased platelet count has been observed in some patients taking sotatercept including severe thrombocytopenia (platelet count $< 50 \times 10^9/L$). Thrombocytopenia was reported more frequently in patients also receiving prostacyclin infusion (7.7% to 24.5%) compared to patients not receiving prostacyclin infusion (0.0% to 3.7%) (see section 4.8). Severe thrombocytopenia may increase the risk of bleeding events. Platelet count should be monitored before each dose for the first 5 doses, or longer if values are unstable, and every 3 to 6 months thereafter to determine whether dose adjustments are required (see section 4.2).

Serious bleeding

In clinical studies, serious bleeding events (including gastrointestinal, intracranial haemorrhage) have been observed in 4.3% to 7.0% of patients during treatment with sotatercept (see section 4.8). Patients with serious bleeding events were more likely to be on prostacyclin background therapy and/or antithrombotic agents, have low platelet count, or be 65 years of age or older. Patients should be advised about any signs and symptoms of blood loss. A physician should evaluate and treat bleeding events accordingly. Sotatercept should not be administered if the patient is experiencing a serious bleeding event.

Limitation of the clinical data

The clinical studies did not include participants with human immunodeficiency virus (HIV)-, portal hypertension-, schistosomiasis-, or pulmonary veno occlusive disease (PVOD)-associated PAH.

Excipients with known effect

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium free'.

This medicinal product contains 0.20 mg of polysorbate 80 in each mL of reconstituted solution. Polysorbates may cause allergic reactions.

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

4.6 Fertility, pregnancy and lactation

Women of childbearing potential

Pregnancy testing is recommended for women of childbearing potential before starting treatment. Women of childbearing potential should use effective contraception during treatment and for at least 4 months after the last dose if treatment is discontinued (see section 5.3).

Pregnancy

There are no data from the use of sotatercept in pregnant women. Studies in animals have shown reproductive toxicity (increases in post-implantation losses, reduction in foetal body weights, and delays in ossification) (see section 5.3).

Winrevair is not recommended during pregnancy and in women of childbearing potential not using contraception.

Breast-feeding

It is unknown whether sotatercept/metabolites are excreted in human milk. A risk to newborns/infants cannot be excluded.

Breast-feeding should be discontinued during treatment and for 4 months after the last dose of treatment.

Fertility

Based on findings in animals, sotatercept may impair female and male fertility (see section 5.3).

4.7 Effects on ability to drive and use machines

Sotatercept has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

Summary of safety profile

The most frequently reported adverse reactions in either STELLAR, ZENITH or HYPERION (highest frequency among the studies) were epistaxis (45.3%), headache (26.7%), telangiectasia (26.3%), diarrhoea (25.6%), increased haemoglobin (15.1%), thrombocytopenia (15.1%), dizziness (14.7%), back pain (14%), rash (12.3%), gastrointestinal tract bleeding (11.6%), and gingival bleeding (10.5%).

The most frequently reported serious adverse reactions were thrombocytopenia (< 1.2%), epistaxis (< 1.2%) and dizziness (< 1.2%).

The most common adverse reactions leading to discontinuation were epistaxis and telangiectasia.

Tabulated list of adverse reactions

The safety of sotatercept was evaluated in the phase 3 placebo-controlled studies STELLAR, ZENITH, and HYPERION, which included 163, 86, and 160 patients with PAH treated with sotatercept, respectively (see section 5.1). The median duration of treatment with sotatercept was 313 days in STELLAR, 434.5 days in ZENITH, and 442.5 days in HYPERION.

Table 3 shows the adverse reactions reported with sotatercept in placebo-controlled clinical studies and post-marketing surveillance. These are listed by MedDRA system organ class and by frequency. Frequencies are defined as very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1\ 000$ to $< 1/100$), rare ($\geq 1/10\ 000$ to $< 1/1\ 000$), and very rare ($< 1/10\ 000$), and not known (cannot be estimated from available post-marketing data).

Table 3: Adverse reactions

System organ class	Frequency	Adverse reaction
Infections and infestations	Common	Urinary tract infections
Blood and lymphatic system disorders	Very common	Thrombocytopenia ^{1,2} Increased haemoglobin ¹
Nervous system disorders	Very common	Dizziness Headache
Cardiac disorders	Not known	Pericardial effusion ¹
Respiratory, thoracic and mediastinal disorders	Very common	Epistaxis
	Uncommon	Intrapulmonary shunt ³
Gastrointestinal disorders	Very common	Diarrhoea Gingival bleeding ⁴ Gastrointestinal tract bleeding ^{4,5}
	Common	Colonic angiodysplasia
Skin and subcutaneous tissue disorders	Very common	Telangiectasia ¹ Rash
	Common	Erythema Skin hypopigmentation
Musculoskeletal and connective tissue disorders	Very common	Back pain ⁴
General disorders and administration site conditions	Common	Injection site pruritus
Investigations	Common	Increased blood pressure ^{1,6}

¹ See description of selected adverse reactions

² Includes 'thrombocytopenia' and 'platelet count decreased'

³ See 'Long-term safety data'

⁴ The frequency category is based on ZENITH

⁵ Includes 'gastrointestinal haemorrhage', 'upper gastrointestinal haemorrhage', 'haematemesis', 'lower gastrointestinal haemorrhage', 'haematochezia', 'rectal haemorrhage', 'melaena' and 'gastritis haemorrhagic'

⁶ Includes 'hypertension', 'blood pressure diastolic increased' and 'blood pressure increased'

Description of selected adverse reactions

Increased haemoglobin

In STELLAR, increased Hgb ('haemoglobin increased' and 'polycythaemia') was reported in 8.6% of patients taking sotatercept. Based on laboratory data, moderate elevations in Hgb (> 1.24 mmol/L (2 g/dL) above ULN) occurred in 15.3% of patients taking sotatercept.

In ZENITH, increased Hgb was reported in 15.1% of patients taking sotatercept. Based on laboratory data, moderate elevations in Hgb occurred in 7.1% of patients taking sotatercept.

In HYPERION, increased Hgb was reported in 11.3% of patients taking sotatercept. Based on laboratory data, moderate elevations in Hgb occurred in 5.7% of patients taking sotatercept.

Increases in Hgb were managed by dose adjustments (see sections 4.2 and 4.4).

Thrombocytopenia

In STELLAR, thrombocytopenia ('thrombocytopenia' and 'platelet count decreased') was reported in 10.4% of patients taking sotatercept. Severe reduction in platelet count $< 50 \times 10^9/L$ occurred in 3.1% of patients taking sotatercept. Thrombocytopenia was reported more frequently in patients also receiving prostacyclin infusion (21.5%) compared to patients not receiving prostacyclin infusion (3.1%).

In ZENITH, thrombocytopenia was reported in 15.1% of patients taking sotatercept. Severe reduction in platelet count $< 50 \times 10^9/L$ occurred in 6.0% of patients taking sotatercept. Thrombocytopenia was reported only in patients also receiving prostacyclin infusion (24.5%).

In HYPERION, thrombocytopenia was reported in 4.4% of patients taking sotatercept. No severe reduction in platelet count $< 50 \times 10^9/L$ occurred in patients taking sotatercept. Thrombocytopenia was reported more frequently in patients also receiving prostacyclin infusion (7.7%) compared to patients not receiving prostacyclin infusion (3.7%).

Thrombocytopenia was managed by dose adjustments (see sections 4.2 and 4.4).

Telangiectasia

In STELLAR, telangiectasia was observed in 16.6% of patients taking sotatercept. The median time to onset was 18.6 weeks. Discontinuations of treatment due to telangiectasia were 1% in the sotatercept group.

In ZENITH, telangiectasia was observed in 25.6% of patients taking sotatercept. The median time to onset was 12.8 weeks. There were no discontinuations of treatment due to telangiectasia in the sotatercept group.

In HYPERION, telangiectasia, was observed in 26.3% of patients taking sotatercept. The median time to onset was 19.6 weeks. Discontinuations of treatment due to telangiectasia were 0.6% in the sotatercept group.

Increased blood pressure

In STELLAR, increased blood pressure was reported in 4.3% of patients taking sotatercept. In patients taking sotatercept, mean systolic blood pressure increased from baseline by 2.2 mmHg and diastolic blood pressure increased by 4.9 mmHg at 24 weeks.

In ZENITH, increased blood pressure was reported in 2.3% of patients taking sotatercept. In patients taking sotatercept, mean systolic blood pressure increased from baseline by 3.1 mmHg and diastolic blood pressure increased by 5.1 mmHg at 24 weeks.

In HYPERION, increased blood pressure was reported in 6.9% of patients taking sotatercept. In patients taking sotatercept, mean systolic blood pressure increased from baseline by 3.6 mmHg and diastolic blood pressure increased by 4.5 mmHg at 24 weeks.

Pericardial effusion

Cases of new-onset or worsening of pericardial effusions (including cardiac tamponade) have been reported in patients treated with sotatercept, despite improved or stable PAH haemodynamics. Most cases were reported in patients with PAH associated with connective tissue disease, pre-existing pericardial effusion, or both; most also received prostacyclin analogues.

Elderly

With the exception of bleeding events (a collective group of adverse events of clinical interest), there were no differences in safety between the < 65-year-old and ≥ 65-year-old subgroups.

In STELLAR, bleeding events occurred more commonly in the older sotatercept subgroup (52% versus 31.9% in patients < 65-year-old); however, there was no notable imbalance between age categories for any specific bleeding event. Serious bleeding occurred in 3.6% of patients < 65-year-old and in 8.0% of patients ≥ 65-year-old taking sotatercept.

In ZENITH, bleeding events occurred more commonly in the older sotatercept subgroup (73.3% versus 60.7% in patients < 65-year-old). Serious bleeding occurred in 3.6% of patients < 65-year-old and in 13.3% of patients ≥ 65-year-old taking sotatercept.

In HYPERION, bleeding events occurred more commonly in the older sotatercept subgroup (55.9% vs 38% in patients < 65-year-old). Serious bleeding occurred in 2.2% of patients < 65-year-old and in 13.2% of patients ≥ 65-year-old taking sotatercept.

Long-term safety data

Pooled long-term safety data are available from 431 patients who participated in phase 2 and phase 3 clinical studies (PULSAR, SPECTRA, and STELLAR). A majority of these patients continued into SOTERIA, an ongoing open-label follow-up study of the long-term safety and efficacy of sotatercept. The mean duration of exposure was 173 weeks, with a maximum exposure of 355 weeks. The safety profile was generally similar to that observed in the pivotal STELLAR study. Right-to-left intrapulmonary shunting has been reported in participants who developed worsening hypoxemia despite improved PAH haemodynamics.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](#).

4.9 Overdose

In a phase 1 healthy volunteer study, one participant dosed at 1 mg/kg of sotatercept experienced increased Hgb associated with symptomatic hypertension that improved with phlebotomy.

In the event of overdose in a patient with PAH, increases in Hgb and blood pressure should be closely monitored, and supportive care should be provided as appropriate (see sections 4.2 and 4.4). Sotatercept is not dialyzable during haemodialysis.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: antihypertensives, antihypertensives for pulmonary arterial hypertension. ATC code: C02KX06

Mechanism of action

Sotatercept is an activin signalling inhibitor with high selectivity for Activin-A, a dimeric glycoprotein which belongs to the transforming growth factor-β (TGF-β) superfamily of ligands. Activin-A binds to

the activin receptor type IIA (ActRIIA) regulating key signalling for inflammation, cell proliferation, apoptosis, and tissue homeostasis.

Activin-A levels are increased in PAH patients. Activin binding to ActRIIA promotes proliferative signalling while there is a decrease in anti-proliferative bone morphogenetic protein receptor type II (BMPRII) signalling. The imbalance of ActRIIA-BMPRII signalling underlying PAH results in vascular cell hyperproliferation, causing pathological remodelling of the pulmonary arterial wall, narrowing the arterial lumen, increasing pulmonary vascular resistance, and leads to increased pulmonary artery pressure and right ventricular dysfunction.

Sotatercept consists of a recombinant homodimeric activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein, which acts as a ligand trap that scavenges excess Activin-A and other ligands for ActRIIA to inhibit activin signalling. As a result, sotatercept rebalances the pro-proliferative (ActRIIA/Smad2/3-mediated) and anti-proliferative (BMPRII/Smad1/5/8-mediated) signalling to modulate vascular proliferation.

Pharmacodynamic effects

A phase 2 clinical study (PULSAR) assessed pulmonary vascular resistance (PVR) in patients with PAH after 24 weeks of treatment with sotatercept. The decrease from baseline in PVR was significantly greater in the sotatercept 0.7 mg/kg and 0.3 mg/kg groups compared with the placebo group. The placebo-adjusted least squares (LS) mean difference from baseline was -269.4 dyn*sec/cm⁵ (95% CI: -365.8, -173.0) for the sotatercept 0.7 mg/kg group and -151.1 dyn*sec/cm⁵ (95% CI: -249.6, -52.6) for the sotatercept 0.3 mg/kg group.

In rat models of PAH, a sotatercept analogue reduced expression of pro-inflammatory markers at the pulmonary arterial wall, reduced leucocyte recruitment, inhibited proliferation of endothelial and smooth muscle cells, and promoted apoptosis in diseased vasculature. These cellular changes were associated with thinner vessel walls, reversed arterial and right ventricular remodelling, and improved haemodynamics.

Immunogenicity

Anti-drug antibodies (ADA) were detected in 27% of patients in STELLAR, 43% of patients in ZENITH, and 40% of patients in HYPERION. No evidence of ADA impact on pharmacokinetics, efficacy or safety was observed.

Clinical efficacy and safety

STELLAR

The efficacy of sotatercept was evaluated in adult patients with PAH in the pivotal STELLAR study. STELLAR was a double-blind, placebo-controlled, multicentre, parallel-group clinical study in which 323 patients with PAH (WHO FC II or III) were randomised 1:1 to sotatercept (starting dose 0.3 mg/kg escalated to target dose 0.7 mg/kg) (n = 163) or placebo (n = 160) administered subcutaneously once every 3 weeks. Patients continued their treatment assignment in the long-term double-blind treatment period until all patients completed Week 24.

Participants in this study were adults with a median age of 48.0 years (range: 18 to 82 years), of which 16.7% were ≥ 65 years of age. Median weight was 68.2 kg (range: 38.0 to 141.3 kg); 89.2% of participants were White, and 79.3% were not Hispanic or Latino; and 79.3% were female. The most common PAH aetiologies were idiopathic PAH (58.5%), heritable PAH (18.3%), and PAH associated with connective tissue diseases (14.9%), PAH associated with simple congenital heart disease with repaired systemic-to-pulmonary shunts (5%), or drug or toxin-induced PAH (3.4%). The mean time since PAH diagnosis to screening was 8.76 years.

Most participants were receiving either triple (61.3%) or double (34.7%) background PAH therapy, and more than one-third (39.9%) were receiving prostacyclin infusions. The proportions of participants in WHO FC II was 48.6% and in WHO FC III was 51.4%. The STELLAR study excluded

patients diagnosed with HIV-associated PAH, PAH associated with portal hypertension, schistosomiasis-associated PAH, and PVOD.

The primary efficacy endpoint was the change from baseline at Week 24 in 6-Minute Walk Distance (6MWD). In the sotatercept treatment group, the median of the placebo-adjusted change in 6MWD from baseline at Week 24 was 40.8 meters (95% CI: 27.5, 54.1; $p < 0.001$). The median of the placebo-adjusted changes in 6MWD at Week 24 were also evaluated in subgroups. The treatment effect was consistent across the different subgroups including sex, PAH diagnostic group, background therapy at baseline, prostacyclin infusion therapy at baseline, WHO FC, and baseline PVR.

The secondary endpoints included improvements in multicomponent improvement (MCI), PVR, N-terminal pro-B-type natriuretic peptide (NT-proBNP), WHO FC, time to death or first occurrence of clinical worsening events.

MCI was a pre-defined endpoint measured by the proportion of patients achieving all three of the following criteria at Week 24 relative to baseline: improvement in 6MWD (increase ≥ 30 m), improvement in NT-proBNP (decrease in NT-proBNP $\geq 30\%$ or maintenance/achievement of NT-proBNP level < 300 ng/L), and improvement in WHO FC or maintenance of WHO FC II.

Disease progression was measured by the time to death or first occurrence of a clinical worsening event. Clinical worsening events included worsening-related listing for lung and/or heart transplant, need to initiate rescue therapy with an approved background PAH therapy or the need to increase the dose of infusion prostacyclin by $\geq 10\%$, need for atrial septostomy, hospitalisation for worsening PAH (≥ 24 hours), or deterioration of PAH (worsened WHO FC and decrease in 6MWD $\geq 15\%$ with both events occurring at the same time or different times). Clinical worsening events and death were captured until the last patient completed the Week 24 visit (data up to the data cutoff; median duration of exposure 33.6 weeks).

At Week 24, 38.9% of sotatercept-treated patients showed improvement in MCI versus 10.1% in the placebo group ($p < 0.001$). The median treatment difference in PVR between sotatercept and placebo group was -234.6 dyn*sec/cm⁵ (95% CI: -288.4 , -180.8 ; $p < 0.001$). The median treatment difference in NT-proBNP between the sotatercept and placebo groups was -441.6 pg/mL (95% CI: -573.5 , -309.6 ; $p < 0.001$). Improvement in WHO FC from baseline occurred in 29% of patients in sotatercept versus 13.8% in placebo ($p < 0.001$).

Treatment with sotatercept resulted in an 82% reduction (HR 0.182, 95% CI: 0.075, 0.441; $p < 0.001$) in the occurrence of death or clinical worsening events compared to placebo (see Table 4). The treatment effect of sotatercept versus placebo started by Week 10 and continued for the duration of the study.

Table 4: Death or clinical worsening events in STELLAR

	Sotatercept (N = 163)	Placebo (N = 160)
Total number of subjects who experienced death or at least one clinical worsening event, n (%)	7 (4.3)	29 (18.1)
Assessment of death or first occurrence of clinical worsening events*, n (%)		
Death	2 (1.2)	6 (3.8)
Worsening-related listing for lung and/or heart transplant	1 (0.6)	1 (0.6)
Need for atrial septostomy	0 (0.0)	0 (0.0)
PAH-specific hospitalisation (≥ 24 hours)	0 (0.0)	8 (5.0)
Deterioration of PAH [†]	4 (2.5)	15 (9.4)

* A subject can have more than one assessment recorded for their first event of clinical worsening. There were 2 participants receiving placebo and no participant receiving sotatercept who had more than one assessment recorded for their first event of clinical worsening. This analysis excluded the component “need to initiate rescue therapy with an approved PAH therapy or need to increase the dose of infusion prostacyclin by 10% or more”.

[†] Deterioration of PAH is defined by both of the following events occurring at any time, even if they began at different times, as compared to their baseline values: (a) Worsened WHO functional class (II to III, III to IV, II to IV, etc.); and (b) Decrease in 6MWD by $\geq 15\%$ (confirmed by two 6MWTs at least 4 hours apart but no more than one week).

N = number of subjects in FAS population; n = number of subjects in the category. Percentages are calculated as (n/N)*100.

ZENITH

The efficacy of sotatercept was evaluated in adult patients with PAH WHO FC III or IV at high-risk of mortality in the ZENITH study. ZENITH was a double-blind, placebo-controlled, multicentre, parallel-group clinical study in which 172 patients were randomised 1:1 to sotatercept (starting dose of 0.3 mg/kg escalated to target dose 0.7 mg/kg) (n = 86) or placebo (n = 86) administered subcutaneously once every 3 weeks. Patients who did not experience an event of the primary composite endpoint remained in the double-blind, placebo-controlled treatment period, while patients who experienced an event of PAH worsening-related hospitalisation of ≥ 24 hours were eligible to enrol into the open-label, long-term follow-up (LTFU) study SOTERIA.

Participants in the ZENITH study were adults with a median age of 57.5 years (range: 18 to 75 years) of which 29.1% were ≥ 65 years of age; 86.6% of participants were White, and 87.8% were not Hispanic or Latino; and 76.7% were female. The PAH aetiologies studied were idiopathic PAH (50.0%), PAH associated with connective tissue diseases (CTD) (27.9%), heritable PAH (10.5%), drug-induced or toxin-induced PAH (6.4%) and PAH associated with corrected congenital shunts (5.2%). The mean time since PAH diagnosis to screening was 7.68 years. Participants were receiving either triple (72.1%) or double (27.9%) background PAH therapy, and 59.3% were receiving prostacyclin infusion. The proportions of participants in WHO FC III was 74.4% and in WHO FC IV was 25.6%. The REVEAL Lite 2 risk score was < 9 for 2.3% of participants, 9 to 10 for 67.4% of participants, and ≥ 11 for 30.2% of participants. The ZENITH study excluded patients diagnosed with HIV-associated PAH, PAH associated with portal hypertension, PVOD or pulmonary capillary haemangiomatosis or overt signs of capillary and/or venous involvement.

The primary efficacy endpoint was the time to first event of all-cause death, lung transplantation, or PAH worsening-related hospitalisation of ≥ 24 hours. Treatment with sotatercept resulted in 76% reduction (HR: 0.24; 95% CI: 0.13, 0.43; $p < 0.0001$) in the occurrence of the first event of the primary composite endpoint (see Table 5). Fewer participants in the sotatercept treatment group (15 (17.4%)) than in the placebo group (47 (54.7%)) had an event of the primary composite endpoint as of the data cutoff.

The median time to first event was 9.6 months (95% CI: 6.2, 14.8) in the placebo group. The Kaplan-Meier curves began to separate at approximately Week 5, and the separation increased for the remainder of the study (see Figure 1). The treatment effect was consistent across the different subgroups including age, sex, PAH subtype (CTD-associated versus not CTD-associated), WHO FC,

double versus triple background therapy at baseline, prostacyclin infusion therapy at baseline, baseline PVR, and baseline eGFR.

Table 5: Components of the primary endpoint in ZENITH

	Sotatercept (N = 86) n (%)	Placebo (N = 86) n (%)	Hazard ratio (95% CI) p-value^a
Number (%) of participants with ≥ 1 primary event during or post ZENITH	15 (17.4)	47 (54.7)	0.24 (0.13, 0.43) < 0.0001
First event of the composite of the primary endpoint, by component ^b			
All-cause death ^c	6 (7.0)	3 (3.5)	
Lung transplantation	1 (1.2)	1 (1.2)	
PAH worsening related hospitalisation of ≥ 24 hours	8 (9.3)	43 (50.0)	
Participants with any events of the components of the composite ^d			
All-cause death ^{c,e}	7 (8.1)	13 (15.1)	
Lung transplantation	1 (1.2)	6 (7.0)	
PAH worsening-related hospitalisation of ≥ 24 hours	8 (9.3)	43 (50.0)	

^a The primary composite endpoint analysis includes the first occurrence of an adjudicated morbidity-mortality event up to the data cutoff. All pre-cutoff deaths are included, regardless of adjudication and whether they occurred during or post ZENITH.


^b Participants who experienced > 1 component are counted toward only the component that occurred first.

^c Includes all deaths up to the data cutoff, except for those occurring after lung transplantation or enrolment in SOTERIA.

^d Shows each component of the composite primary endpoint as a standalone outcome. A participant is included in more than one row if multiple events meeting the primary endpoint definition were observed.

^e Corresponds to the first secondary endpoint of ZENITH.

Figure 1: Time to first event of all-cause death, lung transplantation, or PAH worsening-related hospitalisation of ≥ 24 hours in ZENITH Kaplan-Meier plot



n=number of participants at risk

Based on the primary endpoint result, the study was stopped for favourable efficacy at the interim analysis. The primary analysis of the first secondary endpoint in the hierarchical testing strategy, overall survival (OS), included all deaths up to the data cutoff, except for those occurring after lung transplantation or enrolment in a long-term follow-up study (see Table 5). The point estimate for the OS HR favoured the sotatercept treatment group over the placebo group (HR: 0.42; 95% CI: 0.17, 1.07; $p = 0.0313$), but the boundary for statistical significance at the interim analysis ($p < 0.0021$) was not crossed.

Other secondary endpoints included improvements in transplant-free survival, NT-proBNP, mean pulmonary arterial pressure (PAP), PVR, 6MWD, cardiac output, and WHO FC.

The point estimate for the transplant-free survival favoured the sotatercept treatment group over the placebo group (HR: 0.34; 95% CI: 0.15, 0.78). At Week 24, the median treatment difference in NT-proBNP between the sotatercept and placebo groups was -2339.1 pg/mL (95% CI: (-3378.7 to -1299.4)). The median treatment difference in mean PAP between the sotatercept and placebo groups was -21.2 mm Hg (95% CI: -27.8 to -14.6). The median treatment difference in PVR between the sotatercept and placebo groups was -339.6 dyn*sec/cm⁵ (95% CI: -511.1 to -168.1). The median treatment difference in 6MWD between the sotatercept and placebo groups was 63.0 m (95% CI: 23.2 to 102.7). The median treatment difference in cardiac output between the sotatercept and placebo groups was 0.5 L/min (95% CI: -0.2 to 1.2). Improvement in WHO FC from baseline occurred in 55.8% of patients in sotatercept versus 27.9% in placebo.

HYPERION

The efficacy of sotatercept in adult patients with newly diagnosed PAH (WHO FC II or III, diagnosis within 12 months prior to screening) at intermediate to high-risk of disease progression was evaluated in HYPERION. HYPERION was a global, double-blind, placebo-controlled clinical study in which 320 patients were randomised 1:1 to sotatercept (starting dose of 0.3 mg/kg escalated to target dose 0.7 mg/kg) (n = 160) or placebo (n = 160) administered subcutaneously once every 3 weeks.

HYPERION was stopped early based on the positive results from the interim analysis of the ZENITH study and a review of the totality of data from the sotatercept clinical program.

Participants in this study were adults with a median age of 60.0 years (range: 18 to 88 years) of whom 40.6% were ≥ 65 years of age, 86.3% of participants were White, 76.6% were not Hispanic or Latino, and 72.5% were female. The PAH aetiologies studied were idiopathic PAH (59.4%), PAH associated with CTD (30.3%), heritable PAH (5.9%), drug or toxin induced PAH (2.5%), and PAH associated with simple congenital heart disease with repaired systemic-to-pulmonary shunts (at least 1 year following shunt repair (1.9%)). The mean time since PAH diagnosis was 0.7 years. All participants were receiving either double (72.2%) or triple (27.8%) background PAH therapy, and 16.6% were receiving prostacyclin infusion. The proportions of participants in WHO FC II was 21.3% and in WHO FC III was 78.8%. The REVEAL Lite 2 risk score was < 6 for 20.6% of participants, 6 to 7 for 50.9% of participants, and ≥ 8 for 28.1% of participants. The COMPERA 2 risk score was low for 1.9% of participants, intermediate-low for 64.1% of participants, intermediate-high for 32.2% of participants, high for 1.6% of participants, and missing for 0.3% of participants. The HYPERION study excluded participants diagnosed HIV-associated PAH, PAH associated with portal hypertension, schistosomiasis-associated PAH, PVOD, and pulmonary capillary hemangiomatosis.

The primary efficacy endpoint was time to clinical worsening (TTCW), defined as the time to death or the first confirmed morbidity event. Events comprising this endpoint included all-cause death, non-planned PAH worsening-related hospitalisation of ≥ 24 hours, atrial septostomy, lung transplantation, and deterioration in 6MWD from baseline combined with at least one of the following: worsening of WHO FC, signs/symptoms of increased right heart failure, or addition of a new background PAH therapy or change to a parenteral route of administration.

In the sotatercept treatment group, the risk of experiencing a first clinical worsening event was 76% lower compared with the placebo group (HR: 0.24; 95% CI: 0.14, 0.41; $p < 0.0001$) (see Table 6). Fewer participants in the sotatercept group (17 (10.6%)) than in the placebo group (59 (36.9%)) had a primary endpoint event.

The median TTCW was 23.0 months (95% CI: 17.3, NR) in the placebo group. The Kaplan-Meier curves showed early separation beginning at approximately Week 5 and with increasing separation for the remainder of the study (see Figure 2). The treatment effect was consistent across subgroups: age, sex, PAH subtype (idiopathic PAH, CTD-associated PAH), double versus triple background PAH therapy, WHO FC, prostacyclin infusion versus non prostacyclin infusion therapy, PVR, eGFR, REVEAL Lite 2 score, intermediate-low versus intermediate-high COMPERA 2 risk score.

Table 6: Components of the primary endpoint in HYPERION

	Sotatercept (N = 160) n (%)	Placebo (N = 160) n (%)	Hazard Ratio (95% CI) p-value
Number (%) of participants with ≥ 1 primary event during or post-HYPERION*	17 (10.6)	59 (36.9)	0.24 (0.14, 0.41) < 0.0001
First event of the composite of the primary endpoint, per component†			
All cause death	7 (4.4)	5 (3.1)	
Non-planned PAH-related hospitalisation of > 24 hours	2 (1.3)	12 (7.5)	
Atrial septostomy	0	0	
Lung transplant	0	0	
Deterioration in performance in exercise due to PAH	8 (5.0)	46 (28.8)	
Participants with any events of the components of the composite‡			
All-cause death	7 (4.4)	6 (3.8)	
Non-planned PAH-related hospitalization of ≥ 24 hours	3 (1.9)	14 (8.8)	
Atrial septostomy	0	0	
Lung transplant	0	0	
Deterioration in performance in exercise due to PAH§	8 (5.0)	46 (28.8)	


* The primary composite endpoint analysis includes the first occurrence of an adjudicated clinical worsening event. All deaths are included, regardless of adjudication and regardless of whether they occurred during or post-HYPERION, except for those occurring after enrollment in SOTERIA.

† Participants who experienced > 1 component are counted toward only the component that occurred first. Participants who experienced multiple components simultaneously as their first event are counted toward each applicable first component.

‡ Shows each component of the composite primary endpoint as a standalone outcome. A participant is included in more than one row if multiple events meeting primary endpoint definition were observed.

§ Defined as a decrease in 6MWD from the average of the screening on 2 consecutive tests (which must be at least 4 hours apart) and at least 1 of the following: worsening of WHO FC, signs/symptoms of increased right heart failure; or addition/change of a background PAH therapy.

Figure 2: Time to first clinical worsening event in HYPERION Kaplan-Meier plot



n = number of subjects at risk

The secondary endpoints included improvements in multicomponent improvement (MCI), NT-proBNP, WHO FC, and 6MWD.

MCI was measured by the proportion of participants achieving all of the following at Week 24 relative to baseline: improvement in 6MWD (increase ≥ 30 m), improvement in NT-proBNP (decrease in NT-proBNP $\geq 30\%$ or maintenance/achievement of NT-proBNP level < 300 ng/L), and improvement in WHO FC or maintenance of WHO FC II. For each component of the MCI definition, the observed proportion of participants was higher in the sotatercept group compared with the placebo group. The proportion of participants who met all three MCI criteria was significantly greater in the sotatercept group (29.4%) than in the placebo group (14.6%) ($p = 0.003$). At week 24, the median treatment difference in 6MWD between the sotatercept and placebo groups was 21.4 m (95% CI: 4.65, 38.24). The median treatment difference in NT-proBNP between the sotatercept and placebo groups was -308.6 pg/mL (95% CI: -434.84, -182.37). Improvement in WHO FC from baseline occurred in 55.2% of patients in the sotatercept group versus 38.9% in the placebo group.

Paediatric population

The European Medicines Agency has deferred the obligation to submit the results of studies with Winrevair in one or more subsets of the paediatric population in the treatment of pulmonary arterial hypertension (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

In patients with PAH, in the phase 2 and phase 3 studies PULSAR, SPECTRA, and STELLAR, the geometric mean (%Coefficient of variation (CV %)) steady-state AUC and steady-state peak concentration ($C_{\max}$) at the dose of 0.7 mg/kg every 3 weeks were 171.3 mcg×d/mL (34.2%) and 9.7 mcg/mL (30%), respectively. Sotatercept AUC and $C_{\max}$ increase proportionally with dose. Steady state is achieved after approximately 15 weeks of treatment. The accumulation ratio of sotatercept AUC was approximately 2.2. Sotatercept exposure in participants with PAH in the phase 3 ZENITH study were consistent with the above data.

Absorption

The subcutaneous (SC) formulation has an absolute bioavailability of approximately 66% based on population pharmacokinetics analysis. The maximum sotatercept concentration is achieved at a median time to peak drug concentration ($T_{\max}$) of approximately 7 days (range from 2 to 8 days) after multiple dosing every 4 weeks.

Distribution

The central volume of distribution (CV%) of sotatercept is approximately 3.6 L (24.7%). The peripheral volume of distribution (CV%) is approximately 1.7 L (73.3%).

Biotransformation

Sotatercept is catabolised by general protein degradation processes.

Elimination

Sotatercept clearance is approximately 0.18 L/day. The geometric mean terminal half-life (CV%) is approximately 21 days (33.8%).

Specific populations

Age, sex, and ethnic origin

No clinically significant differences in sotatercept pharmacokinetics (PK) were observed based on age (18 to 81 years of age), sex, or ethnic origin (82.9% Caucasian, 3.1% Black, 7.1% Asian, and 6.9% other).

Body weight

The clearance and central volume of distribution of sotatercept increase with increasing body weight. The recommended weight-based dosing regimen results in consistent sotatercept exposures.

Renal impairment

Sotatercept pharmacokinetics was comparable in PAH patients with mild to moderate renal impairment (eGFR ranging from 30 to 89 mL/min/1.73m²) to those with normal renal function (eGFR $\geq$ 90 mL/min/1.73m²). Severe renal impairment (eGFR ranging from 15 to 30 mL/min/1.73m², n = 3) had no impact on the PK of sotatercept. Additionally, sotatercept PK is comparable between non-PAH end-stage renal disease (ESRD) patients (eGFR < 15 mL/min/1.73m²) and patients with normal renal function. Sotatercept is not dialyzable during haemodialysis. Limited data are available on the use of sotatercept in PAH patients with severe renal impairment (eGFR < 30 mL/min/1.73m²).

Hepatic impairment

Sotatercept has not been studied in PAH patients with hepatic impairment (Child-Pugh Classification A to C). Hepatic impairment is not expected to influence sotatercept metabolism since sotatercept is metabolised via cellular catabolism.

5.3 Preclinical safety data

No carcinogenicity or mutagenicity studies have been conducted with sotatercept.

Repeat dose toxicity

In rats and monkeys, the longest SC toxicity studies were 3 months and 9 months in duration, respectively. In rats, adverse findings included efferent duct/testicular degeneration, adrenal gland congestion/necrosis, and membranoproliferative glomerulonephritis and tubulointerstitial nephritis in the kidneys. Kidney changes were not reversible following a 1-month recovery period. In monkeys, adverse changes included increased interstitial matrix at the corticomedullary junction, decreased glomerular tuft size, glomerulonephritis and tubulointerstitial nephritis in the kidney. Kidney changes in monkeys partially resolved following a 3-month recovery period. At the no observed adverse effect level (NOAEL) in rats and monkeys, sotatercept exposures were ≤ 2 -times the clinical exposure at the maximum recommended human dose (MRHD). Other findings that occurred at clinical exposure margins in monkeys included hepatic inflammatory infiltrates, lymphoid depletion in spleen, and inflammatory infiltrates in the choroid plexus.

Reproductive toxicity

In a female fertility study, oestrous cycle duration was increased, pregnancy rates were decreased, there were increases in pre-implantation and post-implantation loss and reductions in live litter size. At the NOAEL for female fertility endpoints, sotatercept exposure was 2-times the clinical AUC at the MRHD.

In males, there were non-reversible histologic changes in the efferent ducts, testes, and epididymides. Histomorphologic changes in rat testes correlated to decreased fertility index that reversed during the 13-week treatment-free period. A NOAEL for testicular histologic changes was not established and the NOAEL for male fertility functional changes provides a systemic exposure 2-times the clinical exposure at the MRHD.

In embryo-fetal developmental toxicity studies, effects in rats and rabbits included reductions in numbers of live foetuses and fetal body weights, delays in ossification, and increases in resorptions and post-implantation losses. In rats only, there were also skeletal variations (increased number of supernumerary ribs and changes in the number of thoracic or lumbar vertebrae). At the NOAEL in rats and rabbits, sotatercept exposures were 2-times and 0.4-times, respectively, the clinical exposure at the MRHD.

In a pre- and postnatal development study in rats, no sotatercept related adverse effects were observed in first filial generation (F1) pups from dams dosed during gestation at estimated exposures up to 2-times the MRHD. In F1 pups from dams dosed during lactation, decreases in pup weight correlated with delays in sexual maturation. The NOAEL for effects on growth and maturation in pups provides a systemic exposure 0.6-times the clinical exposure at the MRHD.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Powder

Citric acid monohydrate (E330)
Sodium citrate (E331)
Polysorbate 80 (E433)
Sucrose

Solvent

Water for injections

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

6.3 Shelf life

Unopened vial

4 years

After reconstitution

Biochemical and biophysical in-use stability has been demonstrated for 4 hours at 30 °C.

From a microbiological point of view, the medicinal product should be used immediately or no longer than 4 hours after reconstitution.

If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.

6.4 Special precautions for storage

Store in a refrigerator (2 °C – 8 °C). Do not freeze.

Store in the original package in order to protect from light.

For storage conditions after reconstitution of the medicinal product, see section 6.3.

6.5 Nature and contents of container

Winrevair 45 mg powder and solvent for solution for injection

2 mL capacity, type I glass vial sealed with a bromobutyl rubber stopper with polymer coating and aluminium seal with lime polypropylene flip-off cap containing 45 mg of sotatercept.

Prefilled syringe (type I glass cartridge closed with a bromobutyl rubber stopper) with 1 mL of solvent.

Winrevair 60 mg powder and solvent for solution for injection

2 mL capacity, type I glass vial sealed with a bromobutyl rubber stopper with polymer coating and aluminium seal with burgundy polypropylene flip-off cap containing 60 mg of sotatercept.

Prefilled syringe (type I glass cartridge closed with a bromobutyl rubber stopper) with 1.3 mL of solvent.

Winrevair powder and solvent for solution for injection is available as the following pack sizes:

- Kits containing 1 vial with 45 mg powder, 1 prefilled syringe with 1.0 mL solvent, 1 dosing syringe with 0.1 mL graduations, 1 vial adaptor (13 mm), 1 needle for injection and 4 alcohol wipes.
- Kits containing 2 vials with 45 mg powder, 2 prefilled syringes with 1.0 mL solvent, 1 dosing syringe with 0.1 mL graduations, 2 vial adaptors (13 mm), 1 needle for injection and 8 alcohol

- wipes.
- Kits containing 1 vial with 60 mg powder, 1 prefilled syringe with 1.3 mL solvent, 1 dosing syringe with 0.1 mL graduations, 1 vial adaptor (13 mm), 1 needle for injection and 4 alcohol wipes.
- Kits containing 2 vials with 60 mg powder, 2 prefilled syringes with 1.3 mL solvent, 1 dosing syringe with 0.1 mL graduations, 2 vial adaptors (13 mm), 1 needle for injection and 8 alcohol wipes.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Selecting the appropriate product kit

If a patient's weight requires the use of two 45 mg or two 60 mg vials, a 2-vial kit should be used instead of two 1-vial kit to eliminate the need for multiple injections (see section 6.5).

Reconstitution and administration instructions

Winrevair powder and solvent for solution for injection should be reconstituted before use and administered as a single injection according to patient weight (see section 4.2).

See the separate Instructions for Use booklet provided in the kit for detailed step by step instructions on how to prepare and administer the medicinal product. An overview of the reconstitution and administration instructions is provided below.

Reconstitution

- Remove the kit from the refrigerator and wait 15 minutes to allow the prefilled syringe(s) and medicinal product to come to room temperature prior to preparation.
- Check the vial to ensure the medicinal product is not expired. The powder should be white to off-white and may look like a whole or broken up cake.
- Remove the lid from the vial containing the powder and swab the rubber stopper with an alcohol wipe.
- Attach the vial adaptor to the vial.
- Visually inspect the prefilled syringe for any damage or leaks and the sterile water inside to ensure there are no visible particles.
- Break off the cap of the prefilled syringe and attach the syringe to the vial adaptor.
- Inject all of the sterile water from the attached syringe into the vial containing the powder:
 - The prefilled syringe provided with the vial 45 mg contains 1.0 mL of sterile water.
 - The prefilled syringe provided with the vial 60 mg contains 1.3 mL of sterile water.
 After reconstitution, the 45 mg vial can only provide up to a dose of 0.9 mL of medicinal product and the 60 mg vial can only provide up to a dose of 1.2 mL of medicinal product. The final concentration after reconstitution is 50 mg/mL.
- Gently swirl the vial to reconstitute the medicinal product. Do not shake or vigorously agitate.
- Allow the vial to stand for up to 3 minutes to allow bubbles to disappear.
- Visually inspect the reconstituted solution. When properly mixed, the reconstituted solution should be clear to opalescent and colourless to slightly brownish-yellow, and should not have clumps or powder.
- Unscrew the syringe from the vial adaptor and discard the emptied syringe.
- If prescribed a 2-vial kit, repeat the steps within this section to prepare the second vial.
- Use the reconstituted solution as soon as possible, but no later than 4 hours after reconstitution.

Dosing syringe preparation

- Before preparing the dosing syringe, visually inspect the reconstituted solution. The reconstituted solution should be clear to opalescent and colourless to slightly brownish-yellow,

- and should not have clumps or powder.
- Swab the vial adaptor with an alcohol wipe.
- Remove the dosing syringe from its packaging and attach the syringe to the vial adaptor.
- Turn the syringe and vial upside-down and withdraw the appropriate volume for injection, based on the patient's weight.
 - If the dose amount requires the use of two vials, withdraw the entire contents of the first vial and slowly transfer the entire contents into the second vial, to ensure dose accuracy.
 - Turn the syringe and vial upside-down and withdraw the required amount of medicinal product.
- If necessary, push the plunger in to remove excess medicinal product or air from the syringe.
- Remove the syringe from the vial adaptor and attach the needle.

Administration

Winrevair is to be administered as a single subcutaneous injection.

- Select the injection site on the abdomen (at least 5 cm away from navel), upper thigh, or upper arm and swab with an alcohol wipe. Select a new site for each injection that is not scarred, tender, or bruised.
 - For administration by the patient or caregiver, train them to inject only in the abdomen or upper thigh (see "Instructions for Use" booklet).
- Perform subcutaneous injection.
- Discard the emptied syringe. Do not reuse the syringe.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

See section 4.4 for instructions on the traceability of biological medicinal products.

7. MARKETING AUTHORISATION HOLDER

Merck Sharp & Dohme B.V.
 Waarderweg 39
 2031 BN Haarlem
 The Netherlands

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/24/1850/001
 EU/1/24/1850/002
 EU/1/24/1850/003
 EU/1/24/1850/004

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 22 August 2024

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency <https://www.ema.europa.eu>.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT

Winrevair 45 mg powder for solution for injection

Winrevair 60 mg powder for solution for injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Winrevair 45 mg powder for solution for injection

Each vial contains 45 mg of sotatercept. After reconstitution, each mL of solution contains 50 mg sotatercept.

Winrevair 60 mg powder for solution for injection

Each vial contains 60 mg of sotatercept. After reconstitution, each mL of solution contains 50 mg sotatercept.

Sotatercept is a recombinant homodimeric fusion protein consisting of the extracellular domain of human activin receptor type IIA (ActRIIA) linked to the Fc domain of human IgG1, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Powder for solution for injection (powder for injection).

White to off-white powder.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Winrevair, in combination with other pulmonary arterial hypertension (PAH) therapies, is indicated for the treatment of PAH in adult patients with WHO Functional Class (FC) II, III, and IV (see section 5.1).

4.2 Posology and method of administration

Winrevair treatment should only be initiated and monitored by a physician experienced in the diagnosis and treatment of PAH.

Posology

Winrevair is administered once every 3 weeks as a single subcutaneous injection according to patient weight.

Recommended starting dose

Haemoglobin (Hgb) and platelet count should be obtained prior to the first dose (see section 4.4). Initiation of treatment is contraindicated if platelet count is consistently $< 50 \times 10^9/L$ (see section 4.3).

Treatment is initiated with a single dose of 0.3 mg/kg (see Table 1).

Table 1: Injection volume for dose of 0.3 mg/kg

Patient weight range (kg)	Injection volume (mL)*	Pack type
30.0 – 40.8	0.2	Pack containing 1 x 45 mg vial
40.9 – 57.4	0.3	
57.5 – 74.1	0.4	
74.2 – 90.8	0.5	
90.9 – 107.4	0.6	
107.5 – 124.1	0.7	
124.2 – 140.8	0.8	
140.9 – 157.4	0.9	
157.5 – 174.1	1.0	Pack containing 1 x 60 mg vial
174.2 – 180.0	1.1	

*The concentration of the reconstituted solution is 50 mg/mL (see section 6.6)

Recommended target dose

Three weeks after a single starting dose of 0.3 mg/kg, the dose should be escalated to the recommended target dose of 0.7 mg/kg after verifying acceptable Hgb and platelet count (see section 4.2 “*Dose adjustments due to increase in haemoglobin or decreased platelet count*”). Treatment should be continued at 0.7 mg/kg every 3 weeks unless dose adjustments are required.

Table 2: Injection volume for dose of 0.7 mg/kg

Patient weight range (kg)	Injection volume (mL)*	Pack type
30.0 – 31.7	0.4	Pack containing 1 x 45 mg vial
31.8 – 38.9	0.5	
39.0 – 46.0	0.6	
46.1 – 53.2	0.7	
53.3 – 60.3	0.8	
60.4 – 67.4	0.9	
67.5 – 74.6	1.0	Pack containing 1 x 60 mg vial
74.7 – 81.7	1.1	
81.8 – 88.9	1.2	
89.0 – 96.0	1.3	Pack containing 2 x 45 mg vials
96.1 – 103.2	1.4	
103.3 – 110.3	1.5	
110.4 – 117.4	1.6	
117.5 – 124.6	1.7	
124.7 – 131.7	1.8	
131.8 – 138.9	1.9	Pack containing 2 x 60 mg vials
139.0 – 146.0	2.0	
146.1 – 153.2	2.1	
153.3 – 160.3	2.2	
160.4 – 167.4	2.3	
167.5 and above	2.4	

*The concentration of the reconstituted solution is 50 mg/mL (see section 6.6)

Dose adjustments due to increase in haemoglobin or decreased platelet count

Hgb and platelet count should be monitored for the first 5 doses, or longer if values are unstable. Thereafter, Hgb and platelet count should be verified every 3 to 6 months and the dose adjusted if necessary (see sections 4.4 and 4.8).

Treatment should be delayed for 3 weeks (i.e., one dose delay) if any of the following occur:

- Hgb increases > 1.24 mmol/L (2 g/dL) from the previous dose and is above the upper limit of normal (ULN).
- Hgb increases > 2.48 mmol/L (4 g/dL) from baseline.
- Hgb increases > 1.24 mmol/L (2 g/dL) above ULN.
- Platelet count decreases < 50 x 10⁹/L.

Hgb and platelet count should be obtained again before reinitiating treatment.

For treatment delays lasting > 9 weeks, treatment should be restarted at 0.3 mg/kg, and the dose should be escalated to 0.7 mg/kg after verifying acceptable Hgb and platelet count.

For treatment delays lasting > 9 weeks due to platelet counts consistently < 50 x 10⁹/L, the physician should carry out a benefit/risk re-evaluation for the patient before reinitiating treatment.

Missed dose

If a dose is missed, administer as soon as possible. If the missed dose is not taken within 3 days of the scheduled date, adjust the schedule to maintain 3-week dosing intervals.

Elderly

No dose adjustment is required in elderly patients ≥ 65 years old (see section 5.2).

Renal impairment

No dose adjustment is required based on renal impairment (see section 5.2). Limited data are available

on the use of sotatercept in PAH patients with severe renal impairment (estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m²).

Hepatic impairment

No dose adjustment is required based on hepatic impairment (Child-Pugh Classification A to C). Sotatercept has not been studied in patients with hepatic impairment (see section 5.2).

Paediatric population

The safety and efficacy of Winrevair in children and adolescents below 18 years of age have not yet been established. No data are available.

Method of administration

Winrevair is for single use only.

It should be reconstituted before use. The reconstituted medicinal product is a clear to opalescent and colourless to slightly brownish-yellow solution.

Winrevair should be administered by subcutaneous injection in the abdomen (at least 5 cm away from navel), upper arm, or upper thigh. It should not be injected into sites that are scarred, tender, or bruised. The same injection site should not be used on two consecutive injections.

Refer to section 6.6 for instructions on the proper preparation and administration of Winrevair.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Patients with platelet counts consistently < 50 x 10⁹/L before initiating treatment.

4.4 Special warnings and precautions for use

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Erythrocytosis

Increases in Hgb have been observed in patients during treatment with sotatercept. Severe erythrocytosis may increase the risk of thromboembolic events and hyperviscosity syndrome. Use caution in patients with erythrocytosis who are at increased risk of thromboembolic events. Hgb should be monitored before each dose for the first 5 doses, or longer if values are unstable, and every 3 to 6 months thereafter to determine if dose adjustments are required (see sections 4.2 and 4.8).

Severe thrombocytopenia

Decreased platelet count has been observed in some patients taking sotatercept including severe thrombocytopenia (platelet count < 50 x 10⁹/L). Thrombocytopenia was reported more frequently in patients also receiving prostacyclin infusion (7.7% to 24.5%) compared to patients not receiving prostacyclin infusion (0.0% to 3.7%) (see section 4.8). Severe thrombocytopenia may increase the risk of bleeding events. Platelet count should be monitored before each dose for the first 5 doses, or longer if values are unstable, and every 3 to 6 months thereafter to determine whether dose adjustments are required (see section 4.2).

Serious bleeding

In clinical studies, serious bleeding events (including gastrointestinal, intracranial haemorrhage) have been observed in 4.3% to 7.0% of patients during treatment with sotatercept (see section 4.8). Patients with serious bleeding events were more likely to be on prostacyclin background therapy and/or antithrombotic agents, have low platelet count, or be 65 years of age or older. Patients should be advised about any signs and symptoms of blood loss. A physician should evaluate and treat bleeding events accordingly. Sotatercept should not be administered if the patient is experiencing a serious bleeding event.

Limitation of the clinical data

The clinical studies did not include participants with human immunodeficiency virus (HIV)-, portal hypertension-, schistosomiasis-, or pulmonary veno occlusive disease (PVOD)-associated PAH.

Excipients with known effect

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium free'.

This medicinal product contains 0.20 mg of polysorbate 80 in each mL of reconstituted solution. Polysorbates may cause allergic reactions.

4.5 Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

4.6 Fertility, pregnancy and lactation

Women of childbearing potential

Pregnancy testing is recommended for women of childbearing potential before starting treatment. Women of childbearing potential should use effective contraception during treatment and for at least 4 months after the last dose if treatment is discontinued (see section 5.3).

Pregnancy

There are no data from the use of sotatercept in pregnant women. Studies in animals have shown reproductive toxicity (increases in post-implantation losses, reduction in foetal body weights, and delays in ossification) (see section 5.3).

Winrevair is not recommended during pregnancy and in women of childbearing potential not using contraception.

Breast-feeding

It is unknown whether sotatercept/metabolites are excreted in human milk. A risk to newborns/infants cannot be excluded.

Breast-feeding should be discontinued during treatment and for 4 months after the last dose of treatment.

Fertility

Based on findings in animals, sotatercept may impair female and male fertility (see section 5.3).

4.7 Effects on ability to drive and use machines

Sotatercept has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

Summary of safety profile

The most frequently reported adverse reactions in either STELLAR, ZENITH or HYPERION (highest frequency among the studies) were epistaxis (45.3%), headache (26.7%), telangiectasia (26.3%), diarrhoea (25.6%), increased haemoglobin (15.1%), thrombocytopenia (15.1%), dizziness (14.7%), back pain (14%), rash (12.3%), gastrointestinal tract bleeding (11.6%), and gingival bleeding (10.5%).

The most frequently reported serious adverse reactions were thrombocytopenia (< 1.2%), epistaxis (< 1.2%) and dizziness (< 1.2%).

The most common adverse reactions leading to discontinuation were epistaxis and telangiectasia.

Tabulated list of adverse reactions

The safety of sotatercept was evaluated in the phase 3 placebo-controlled studies STELLAR, ZENITH, and HYPERION, which included 163, 86, and 160 patients with PAH treated with sotatercept, respectively (see section 5.1). The median duration of treatment with sotatercept was 313 days in STELLAR, 434.5 days in ZENITH, and 442.5 days in HYPERION.

Table 3 shows the adverse reactions reported with sotatercept in placebo-controlled clinical studies and post-marketing surveillance. These are listed by MedDRA system organ class and by frequency. Frequencies are defined as very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1\ 000$ to $< 1/100$), rare ($\geq 1/10\ 000$ to $< 1/1\ 000$), and very rare ($< 1/10\ 000$), and not known (cannot be estimated from available post-marketing data).

Table 3: Adverse reactions

System organ class	Frequency	Adverse reaction
Infections and infestations	Common	Urinary tract infections
Blood and lymphatic system disorders	Very common	Thrombocytopenia ^{1,2} Increased haemoglobin ¹
Nervous system disorders	Very common	Dizziness Headache
Cardiac disorders	Not known	Pericardial effusion ¹
Respiratory, thoracic and mediastinal disorders	Very common	Epistaxis
	Uncommon	Intrapulmonary shunt ³
Gastrointestinal disorders	Very common	Diarrhoea Gingival bleeding ⁴ Gastrointestinal tract bleeding ^{4,5}
	Common	Colonic angioectasia
Skin and subcutaneous tissue disorders	Very common	Telangiectasia ¹ Rash
	Common	Erythema Skin hypopigmentation
Musculoskeletal and connective tissue disorders	Very common	Back pain ⁴
General disorders and administration site conditions	Common	Injection site pruritus
Investigations	Common	Increased blood pressure ^{1,6}

¹ See description of selected adverse reactions

² Includes 'thrombocytopenia' and 'platelet count decreased'

³ See 'Long-term safety data'

⁴ The frequency category is based on ZENITH

⁵ Includes 'gastrointestinal haemorrhage', 'upper gastrointestinal haemorrhage', 'haematemesis', 'lower gastrointestinal haemorrhage', 'haematochezia', 'rectal haemorrhage', 'melaena' and 'gastritis haemorrhagic'

⁶ Includes 'hypertension', 'blood pressure diastolic increased' and 'blood pressure increased'

Description of selected adverse reactions

Increased haemoglobin

In STELLAR, increased Hgb ('haemoglobin increased' and 'polycythaemia') was reported in 8.6% of patients taking sotatercept. Based on laboratory data, moderate elevations in Hgb (> 1.24 mmol/L (2 g/dL) above ULN) occurred in 15.3% of patients taking sotatercept.

In ZENITH, increased Hgb was reported in 15.1% of patients taking sotatercept. Based on laboratory data, moderate elevations in Hgb occurred in 7.1% of patients taking sotatercept.

In HYPERION, increased Hgb was reported in 11.3% of patients taking sotatercept. Based on laboratory data, moderate elevations in Hgb occurred in 5.7% of patients taking sotatercept.

Increases in Hgb were managed by dose adjustments (see sections 4.2 and 4.4).

Thrombocytopenia

In STELLAR, thrombocytopenia ('thrombocytopenia' and 'platelet count decreased') was reported in 10.4% of patients taking sotatercept. Severe reduction in platelet count $< 50 \times 10^9/L$ occurred in 3.1% of patients taking sotatercept. Thrombocytopenia was reported more frequently in patients also receiving prostacyclin infusion (21.5%) compared to patients not receiving prostacyclin infusion (3.1%).

In ZENITH, thrombocytopenia was reported in 15.1% of patients taking sotatercept. Severe reduction in platelet count $< 50 \times 10^9/L$ occurred in 6.0% of patients taking sotatercept. Thrombocytopenia was reported only in patients also receiving prostacyclin infusion (24.5%).

In HYPERION, thrombocytopenia was reported in 4.4% of patients taking sotatercept. No severe reduction in platelet count $< 50 \times 10^9/L$ occurred in patients taking sotatercept. Thrombocytopenia was reported more frequently in patients also receiving prostacyclin infusion (7.7%) compared to patients not receiving prostacyclin infusion (3.7%).

Thrombocytopenia was managed by dose adjustments (see sections 4.2 and 4.4).

Telangiectasia

In STELLAR, telangiectasia was observed in 16.6% of patients taking sotatercept. The median time to onset was 18.6 weeks. Discontinuations of treatment due to telangiectasia were 1% in the sotatercept group.

In ZENITH, telangiectasia was observed in 25.6% of patients taking sotatercept. The median time to onset was 12.8 weeks. There were no discontinuations of treatment due to telangiectasia in the sotatercept group.

In HYPERION, telangiectasia, was observed in 26.3% of patients taking sotatercept. The median time to onset was 19.6 weeks. Discontinuations of treatment due to telangiectasia were 0.6% in the sotatercept group.

Increased blood pressure

In STELLAR, increased blood pressure was reported in 4.3% of patients taking sotatercept. In patients taking sotatercept, mean systolic blood pressure increased from baseline by 2.2 mmHg and diastolic blood pressure increased by 4.9 mmHg at 24 weeks.

In ZENITH, increased blood pressure was reported in 2.3% of patients taking sotatercept. In patients taking sotatercept, mean systolic blood pressure increased from baseline by 3.1 mmHg and diastolic blood pressure increased by 5.1 mmHg at 24 weeks.

In HYPERION, increased blood pressure was reported in 6.9% of patients taking sotatercept. In patients taking sotatercept, mean systolic blood pressure increased from baseline by 3.6 mmHg and diastolic blood pressure increased by 4.5 mmHg at 24 weeks.

Pericardial effusion

Cases of new-onset or worsening of pericardial effusions (including cardiac tamponade) have been reported in patients treated with sotatercept, despite improved or stable PAH haemodynamics. Most cases were reported in patients with PAH associated with connective tissue disease, pre-existing pericardial effusion, or both; most also received prostacyclin analogues.

Elderly

With the exception of bleeding events (a collective group of adverse events of clinical interest), there were no differences in safety between the < 65-year-old and ≥ 65-year-old subgroups.

In STELLAR, bleeding events occurred more commonly in the older sotatercept subgroup (52% versus 31.9% in patients < 65-year-old); however, there was no notable imbalance between age categories for any specific bleeding event. Serious bleeding occurred in 3.6% of patients < 65-year-old and in 8.0% of patients ≥ 65-year-old taking sotatercept.

In ZENITH, bleeding events occurred more commonly in the older sotatercept subgroup (73.3% versus 60.7% in patients < 65-year-old). Serious bleeding occurred in 3.6% of patients < 65-year-old and in 13.3% of patients ≥ 65-year-old taking sotatercept.

In HYPERION, bleeding events occurred more commonly in the older sotatercept subgroup (55.9% vs 38% in patients < 65-year-old). Serious bleeding occurred in 2.2% of patients < 65-year-old and in 13.2% of patients ≥ 65-year-old taking sotatercept.

Long-term safety data

Pooled long-term safety data are available from 431 patients who participated in phase 2 and phase 3 clinical studies (PULSAR, SPECTRA, and STELLAR). A majority of these patients continued into SOTERIA, an ongoing open-label follow-up study of the long-term safety and efficacy of sotatercept. The mean duration of exposure was 173 weeks, with a maximum exposure of 355 weeks. The safety profile was generally similar to that observed in the pivotal STELLAR study. Right-to-left intrapulmonary shunting has been reported in participants who developed worsening hypoxemia despite improved PAH haemodynamics.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](#).

4.9 Overdose

In a phase 1 healthy volunteer study, one participant dosed at 1 mg/kg of sotatercept experienced increased Hgb associated with symptomatic hypertension that improved with phlebotomy.

In the event of overdose in a patient with PAH, increases in Hgb and blood pressure should be closely monitored, and supportive care should be provided as appropriate (see sections 4.2 and 4.4). Sotatercept is not dialyzable during haemodialysis.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: antihypertensives, antihypertensives for pulmonary arterial hypertension.
ATC code: C02KX06

Mechanism of action

Sotatercept is an activin signalling inhibitor with high selectivity for Activin-A, a dimeric glycoprotein which belongs to the transforming growth factor- β (TGF- β) superfamily of ligands. Activin-A binds to the activin receptor type IIA (ActRIIA) regulating key signalling for inflammation, cell proliferation, apoptosis, and tissue homeostasis.

Activin-A levels are increased in PAH patients. Activin binding to ActRIIA promotes proliferative signalling while there is a decrease in anti-proliferative bone morphogenetic protein receptor type II (BMPRII) signalling. The imbalance of ActRIIA-BMPRII signalling underlying PAH results in vascular cell hyperproliferation, causing pathological remodelling of the pulmonary arterial wall, narrowing the arterial lumen, increasing pulmonary vascular resistance, and leads to increased pulmonary artery pressure and right ventricular dysfunction.

Sotatercept consists of a recombinant homodimeric activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein, which acts as a ligand trap that scavenges excess Activin-A and other ligands for ActRIIA to inhibit activin signalling. As a result, sotatercept rebalances the pro-proliferative (ActRIIA/Smad2/3-mediated) and anti-proliferative (BMPRII/Smad1/5/8-mediated) signalling to modulate vascular proliferation.

Pharmacodynamic effects

A phase 2 clinical study (PULSAR) assessed pulmonary vascular resistance (PVR) in patients with PAH after 24 weeks of treatment with sotatercept. The decrease from baseline in PVR was significantly greater in the sotatercept 0.7 mg/kg and 0.3 mg/kg groups compared with the placebo group. The placebo-adjusted least squares (LS) mean difference from baseline was -269.4 dyn*sec/cm⁵ (95% CI: -365.8, -173.0) for the sotatercept 0.7 mg/kg group and -151.1 dyn*sec/cm⁵ (95% CI: -249.6, -52.6) for the sotatercept 0.3 mg/kg group.

In rat models of PAH, a sotatercept analogue reduced expression of pro-inflammatory markers at the pulmonary arterial wall, reduced leucocyte recruitment, inhibited proliferation of endothelial and smooth muscle cells, and promoted apoptosis in diseased vasculature. These cellular changes were associated with thinner vessel walls, reversed arterial and right ventricular remodelling, and improved haemodynamics.

Immunogenicity

Anti-drug antibodies (ADA) were detected in 27% of patients in STELLAR, 43% of patients in ZENITH, and 40% of patients in HYPERION. No evidence of ADA impact on pharmacokinetics, efficacy or safety was observed.

Clinical efficacy and safety

STELLAR

The efficacy of sotatercept was evaluated in adult patients with PAH in the pivotal STELLAR study. STELLAR was a double-blind, placebo-controlled, multicentre, parallel-group clinical study in which 323 patients with PAH (WHO FC II or III) were randomised 1:1 to sotatercept (starting dose 0.3 mg/kg escalated to target dose 0.7 mg/kg) (n = 163) or placebo (n = 160) administered subcutaneously once every 3 weeks. Patients continued their treatment assignment in the long-term double-blind treatment period until all patients completed Week 24.

Participants in this study were adults with a median age of 48.0 years (range: 18 to 82 years), of which 16.7% were ≥ 65 years of age. Median weight was 68.2 kg (range: 38.0 to 141.3 kg); 89.2% of participants were White, and 79.3% were not Hispanic or Latino; and 79.3% were female. The most common PAH aetiologies were idiopathic PAH (58.5%), heritable PAH (18.3%), and PAH associated with connective tissue diseases (14.9%), PAH associated with simple congenital heart disease with repaired systemic-to-pulmonary shunts (5%), or drug or toxin-induced PAH (3.4%). The mean time since PAH diagnosis to screening was 8.76 years.

Most participants were receiving either triple (61.3%) or double (34.7%) background PAH therapy, and more than one-third (39.9%) were receiving prostacyclin infusions. The proportions of participants in WHO FC II was 48.6% and in WHO FC III was 51.4%. The STELLAR study excluded patients diagnosed with HIV-associated PAH, PAH associated with portal hypertension, schistosomiasis-associated PAH, and PVOD.

The primary efficacy endpoint was the change from baseline at Week 24 in 6-Minute Walk Distance (6MWD). In the sotatercept treatment group, the median of the placebo-adjusted change in 6MWD from baseline at Week 24 was 40.8 meters (95% CI: 27.5, 54.1; $p < 0.001$). The median of the placebo-adjusted changes in 6MWD at Week 24 were also evaluated in subgroups. The treatment effect was consistent across the different subgroups including sex, PAH diagnostic group, background therapy at baseline, prostacyclin infusion therapy at baseline, WHO FC, and baseline PVR.

The secondary endpoints included improvements in multicomponent improvement (MCI), PVR, N-terminal pro-B-type natriuretic peptide (NT-proBNP), WHO FC, time to death or first occurrence of clinical worsening events.

MCI was a pre-defined endpoint measured by the proportion of patients achieving all three of the following criteria at Week 24 relative to baseline: improvement in 6MWD (increase ≥ 30 m), improvement in NT-proBNP (decrease in NT-proBNP $\geq 30\%$ or maintenance/achievement of NT-proBNP level < 300 ng/L), and improvement in WHO FC or maintenance of WHO FC II.

Disease progression was measured by the time to death or first occurrence of a clinical worsening event. Clinical worsening events included worsening-related listing for lung and/or heart transplant, need to initiate rescue therapy with an approved background PAH therapy or the need to increase the dose of infusion prostacyclin by $\geq 10\%$, need for atrial septostomy, hospitalisation for worsening PAH (≥ 24 hours), or deterioration of PAH (worsened WHO FC and decrease in 6MWD $\geq 15\%$ with both events occurring at the same time or different times). Clinical worsening events and death were captured until the last patient completed the Week 24 visit (data up to the data cutoff; median duration of exposure 33.6 weeks).

At Week 24, 38.9% of sotatercept-treated patients showed improvement in MCI versus 10.1% in the placebo group ($p < 0.001$). The median treatment difference in PVR between sotatercept and placebo group was -234.6 dyn*sec/cm⁵ (95% CI: -288.4 , -180.8 ; $p < 0.001$). The median treatment difference in NT-proBNP between the sotatercept and placebo groups was -441.6 pg/mL (95% CI: -573.5 , -309.6 ; $p < 0.001$). Improvement in WHO FC from baseline occurred in 29% of patients in sotatercept versus 13.8% in placebo ($p < 0.001$).

Treatment with sotatercept resulted in an 82% reduction (HR 0.182, 95% CI: 0.075, 0.441; $p < 0.001$) in the occurrence of death or clinical worsening events compared to placebo (see Table 4). The treatment effect of sotatercept versus placebo started by Week 10 and continued for the duration of the study.

Table 4: Death or clinical worsening events in STELLAR

	Sotatercept (N = 163)	Placebo (N = 160)
Total number of subjects who experienced death or at least one clinical worsening event, n (%)	7 (4.3)	29 (18.1)
Assessment of death or first occurrence of clinical worsening events*, n (%)		
Death	2 (1.2)	6 (3.8)
Worsening-related listing for lung and/or heart transplant	1 (0.6)	1 (0.6)
Need for atrial septostomy	0 (0.0)	0 (0.0)
PAH-specific hospitalisation (≥ 24 hours)	0 (0.0)	8 (5.0)
Deterioration of PAH [†]	4 (2.5)	15 (9.4)

* A subject can have more than one assessment recorded for their first event of clinical worsening. There were 2 participants receiving placebo and no participant receiving sotatercept who had more than one assessment recorded for their first event of clinical worsening. This analysis excluded the component “need to initiate rescue therapy with an approved PAH therapy or need to increase the dose of infusion prostacyclin by 10% or more”.

[†] Deterioration of PAH is defined by both of the following events occurring at any time, even if they began at different times, as compared to their baseline values: (a) Worsened WHO functional class (II to III, III to IV, II to IV, etc.); and (b) Decrease in 6MWD by $\geq 15\%$ (confirmed by two 6MWTs at least 4 hours apart but no more than one week).

N = number of subjects in FAS population; n = number of subjects in the category. Percentages are calculated as $(n/N) \times 100$.

ZENITH

The efficacy of sotatercept was evaluated in adult patients with PAH WHO FC III or IV at high-risk of mortality in the ZENITH study. ZENITH was a double-blind, placebo-controlled, multicentre, parallel-group clinical study in which 172 patients were randomised 1:1 to sotatercept (starting dose of 0.3 mg/kg escalated to target dose 0.7 mg/kg) (n = 86) or placebo (n = 86) administered subcutaneously once every 3 weeks. Patients who did not experience an event of the primary composite endpoint remained in the double-blind, placebo-controlled treatment period, while patients who experienced an event of PAH worsening-related hospitalisation of ≥ 24 hours were eligible to enrol into the open-label, long-term follow-up (LTFU) study SOTERIA.

Participants in the ZENITH study were adults with a median age of 57.5 years (range: 18 to 75 years) of which 29.1% were ≥ 65 years of age; 86.6% of participants were White, and 87.8% were not Hispanic or Latino; and 76.7% were female. The PAH aetiologies studied were idiopathic PAH (50.0%), PAH associated with connective tissue diseases (CTD) (27.9%), heritable PAH (10.5%), drug-induced or toxin-induced PAH (6.4%) and PAH associated with corrected congenital shunts (5.2%). The mean time since PAH diagnosis to screening was 7.68 years. Participants were receiving either triple (72.1%) or double (27.9%) background PAH therapy, and 59.3% were receiving prostacyclin infusion. The proportions of participants in WHO FC III was 74.4% and in WHO FC IV was 25.6%. The REVEAL Lite 2 risk score was < 9 for 2.3% of participants, 9 to 10 for 67.4% of participants, and ≥ 11 for 30.2% of participants. The ZENITH study excluded patients diagnosed with HIV-associated PAH, PAH associated with portal hypertension, PVOD or pulmonary capillary haemangiomatosis or overt signs of capillary and/or venous involvement.

The primary efficacy endpoint was the time to first event of all-cause death, lung transplantation, or PAH worsening-related hospitalisation of ≥ 24 hours. Treatment with sotatercept resulted in 76% reduction (HR: 0.24; 95% CI: 0.13, 0.43; $p < 0.0001$) in the occurrence of the first event of the primary composite endpoint (see Table 5). Fewer participants in the sotatercept treatment group (15 (17.4%)) than in the placebo group (47 (54.7%)) had an event of the primary composite endpoint as of the data cutoff.

The median time to first event was 9.6 months (95% CI: 6.2, 14.8) in the placebo group. The Kaplan-Meier curves began to separate at approximately Week 5, and the separation increased for the remainder of the study (see Figure 1). The treatment effect was consistent across the different subgroups including age, sex, PAH subtype (CTD-associated versus not CTD-associated), WHO FC, double versus triple background therapy at baseline, prostacyclin infusion therapy at baseline, baseline PVR, and baseline eGFR.

Table 5: Components of the primary endpoint in ZENITH

	Sotatercept (N = 86) n (%)	Placebo (N = 86) n (%)	Hazard ratio (95% CI) p-value^a
Number (%) of participants with ≥ 1 primary event during or post ZENITH	15 (17.4)	47 (54.7)	0.24 (0.13, 0.43) < 0.0001
First event of the composite of the primary endpoint, by component ^b			
All-cause death ^c	6 (7.0)	3 (3.5)	
Lung transplantation	1 (1.2)	1 (1.2)	
PAH worsening related hospitalisation of ≥ 24 hours	8 (9.3)	43 (50.0)	
Participants with any events of the components of the composite ^d			
All-cause death ^{c,e}	7 (8.1)	13 (15.1)	
Lung transplantation	1 (1.2)	6 (7.0)	
PAH worsening-related hospitalisation of ≥ 24 hours	8 (9.3)	43 (50.0)	

^a The primary composite endpoint analysis includes the first occurrence of an adjudicated morbidity-mortality event up to the data cutoff. All pre-cutoff deaths are included, regardless of adjudication and whether they occurred during or post ZENITH.


^b Participants who experienced > 1 component are counted toward only the component that occurred first.

^c Includes all deaths up to the data cutoff, except for those occurring after lung transplantation or enrolment in SOTERIA.

^d Shows each component of the composite primary endpoint as a standalone outcome. A participant is included in more than one row if multiple events meeting the primary endpoint definition were observed.

^e Corresponds to the first secondary endpoint of ZENITH.

Figure 1: Time to first event of all-cause death, lung transplantation, or PAH worsening-related hospitalisation of ≥ 24 hours in ZENITH Kaplan-Meier plot



n=number of participants at risk

Based on the primary endpoint result, the study was stopped for favourable efficacy at the interim analysis. The primary analysis of the first secondary endpoint in the hierarchical testing strategy, overall survival (OS), included all deaths up to the data cutoff, except for those occurring after lung transplantation or enrolment in a long-term follow-up study (see Table 5). The point estimate for the OS HR favoured the sotatercept treatment group over the placebo group (HR: 0.42; 95% CI: 0.17, 1.07; $p = 0.0313$), but the boundary for statistical significance at the interim analysis ($p < 0.0021$) was not crossed.

Other secondary endpoints included improvements in transplant-free survival, NT-proBNP, mean pulmonary arterial pressure (PAP), PVR, 6MWD, cardiac output, and WHO FC.

The point estimate for the transplant-free survival favoured the sotatercept treatment group over the placebo group (HR: 0.34; 95% CI: 0.15, 0.78). At Week 24, the median treatment difference in NT-proBNP between the sotatercept and placebo groups was -2339.1 pg/mL (95% CI: (-3378.7 to -1299.4)). The median treatment difference in mean PAP between the sotatercept and placebo groups was -21.2 mm Hg (95% CI: -27.8 to -14.6). The median treatment difference in PVR between the sotatercept and placebo groups was -339.6 dyn*sec/cm⁵ (95% CI: -511.1 to -168.1). The median treatment difference in 6MWD between the sotatercept and placebo groups was 63.0 m (95% CI: 23.2 to 102.7). The median treatment difference in cardiac output between the sotatercept and placebo

groups was 0.5 L/min (95% CI: -0.2 to 1.2). Improvement in WHO FC from baseline occurred in 55.8% of patients in sotatercept versus 27.9% in placebo.

HYPERION

The efficacy of sotatercept in adult patients with newly diagnosed PAH (WHO FC II or III, diagnosis within 12 months prior to screening) at intermediate to high-risk of disease progression was evaluated in HYPERION. HYPERION was a global, double-blind, placebo-controlled clinical study in which 320 patients were randomised 1:1 to sotatercept (starting dose of 0.3 mg/kg escalated to target dose 0.7 mg/kg) (n = 160) or placebo (n = 160) administered subcutaneously once every 3 weeks. HYPERION was stopped early based on the positive results from the interim analysis of the ZENITH study and a review of the totality of data from the sotatercept clinical program.

Participants in this study were adults with a median age of 60.0 years (range: 18 to 88 years) of whom 40.6% were ≥ 65 years of age, 86.3% of participants were White, 76.6% were not Hispanic or Latino, and 72.5% were female. The PAH aetiologies studied were idiopathic PAH (59.4%), PAH associated with CTD (30.3%), heritable PAH (5.9%), drug or toxin induced PAH (2.5%), and PAH associated with simple congenital heart disease with repaired systemic-to-pulmonary shunts (at least 1 year following shunt repair (1.9%)). The mean time since PAH diagnosis was 0.7 years. All participants were receiving either double (72.2%) or triple (27.8%) background PAH therapy, and 16.6% were receiving prostacyclin infusion. The proportions of participants in WHO FC II was 21.3% and in WHO FC III was 78.8%. The REVEAL Lite 2 risk score was < 6 for 20.6% of participants, 6 to 7 for 50.9% of participants, and ≥ 8 for 28.1% of participants. The COMPERA 2 risk score was low for 1.9% of participants, intermediate-low for 64.1% of participants, intermediate-high for 32.2% of participants, high for 1.6% of participants, and missing for 0.3% of participants. The HYPERION study excluded participants diagnosed HIV-associated PAH, PAH associated with portal hypertension, schistosomiasis-associated PAH, PVOD, and pulmonary capillary hemangiomatosis.

The primary efficacy endpoint was time to clinical worsening (TTCW), defined as the time to death or the first confirmed morbidity event. Events comprising this endpoint included all-cause death, non-planned PAH worsening-related hospitalisation of ≥ 24 hours, atrial septostomy, lung transplantation, and deterioration in 6MWD from baseline combined with at least one of the following: worsening of WHO FC, signs/symptoms of increased right heart failure, or addition of a new background PAH therapy or change to a parenteral route of administration.

In the sotatercept treatment group, the risk of experiencing a first clinical worsening event was 76% lower compared with the placebo group (HR: 0.24; 95% CI: 0.14, 0.41; $p < 0.0001$) (see Table 6). Fewer participants in the sotatercept group (17 (10.6%)) than in the placebo group (59 (36.9%)) had a primary endpoint event.

The median TTCW was 23.0 months (95% CI: 17.3, NR) in the placebo group. The Kaplan-Meier curves showed early separation beginning at approximately Week 5 and with increasing separation for the remainder of the study (see Figure 2). The treatment effect was consistent across subgroups: age, sex, PAH subtype (idiopathic PAH, CTD-associated PAH), double versus triple background PAH therapy, WHO FC, prostacyclin infusion versus non prostacyclin infusion therapy, PVR, eGFR, REVEAL Lite 2 score, intermediate-low versus intermediate-high COMPERA 2 risk score.

Table 6: Components of the primary endpoint in HYPERION

	Sotatercept (N = 160) n (%)	Placebo (N = 160) n (%)	Hazard Ratio (95% CI) p-value
Number (%) of participants with ≥ 1 primary event during or post-HYPERION*	17 (10.6)	59 (36.9)	0.24 (0.14, 0.41) < 0.0001
First event of the composite of the primary endpoint, per component†			
All cause death	7 (4.4)	5 (3.1)	
Non-planned PAH-related hospitalisation of > 24 hours	2 (1.3)	12 (7.5)	
Atrial septostomy	0	0	
Lung transplant	0	0	
Deterioration in performance in exercise due to PAH	8 (5.0)	46 (28.8)	
Participants with any events of the components of the composite‡			
All-cause death	7 (4.4)	6 (3.8)	
Non-planned PAH-related hospitalization of ≥ 24 hours	3 (1.9)	14 (8.8)	
Atrial septostomy	0	0	
Lung transplant	0	0	
Deterioration in performance in exercise due to PAH§	8 (5.0)	46 (28.8)	


* The primary composite endpoint analysis includes the first occurrence of an adjudicated clinical worsening event. All deaths are included, regardless of adjudication and regardless of whether they occurred during or post-HYPERION, except for those occurring after enrollment in SOTERIA.

† Participants who experienced > 1 component are counted toward only the component that occurred first. Participants who experienced multiple components simultaneously as their first event are counted toward each applicable first component.

‡ Shows each component of the composite primary endpoint as a standalone outcome. A participant is included in more than one row if multiple events meeting primary endpoint definition were observed.

§ Defined as a decrease in 6MWD from the average of the screening on 2 consecutive tests (which must be at least 4 hours apart) and at least 1 of the following: worsening of WHO FC, signs/symptoms of increased right heart failure; or addition/change of a background PAH therapy.

Figure 2: Time to first clinical worsening event in HYPERION Kaplan-Meier plot



n = number of subjects at risk

The secondary endpoints included improvements in multicomponent improvement (MCI), NT-proBNP, WHO FC, and 6MWD.

MCI was measured by the proportion of participants achieving all of the following at Week 24 relative to baseline: improvement in 6MWD (increase ≥ 30 m), improvement in NT-proBNP (decrease in NT-proBNP $\geq 30\%$ or maintenance/achievement of NT-proBNP level < 300 ng/L), and improvement in WHO FC or maintenance of WHO FC II. For each component of the MCI definition, the observed proportion of participants was higher in the sotatercept group compared with the placebo group. The proportion of participants who met all three MCI criteria was significantly greater in the sotatercept group (29.4%) than in the placebo group (14.6%) ($p = 0.003$). At week 24, the median treatment difference in 6MWD between the sotatercept and placebo groups was 21.4 m (95% CI: 4.65, 38.24). The median treatment difference in NT-proBNP between the sotatercept and placebo groups was -308.6 pg/mL (95% CI: -434.84, -182.37). Improvement in WHO FC from baseline occurred in 55.2% of patients in the sotatercept group versus 38.9% in the placebo group.

Paediatric population

The European Medicines Agency has deferred the obligation to submit the results of studies with Winrevair in one or more subsets of the paediatric population in the treatment of pulmonary arterial hypertension (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

In patients with PAH, in the phase 2 and phase 3 studies PULSAR, SPECTRA, and STELLAR, the geometric mean (%Coefficient of variation (CV %)) steady-state AUC and steady-state peak concentration ($C_{\max}$) at the dose of 0.7 mg/kg every 3 weeks were 171.3 mcg×d/mL (34.2%) and 9.7 mcg/mL (30%), respectively. Sotatercept AUC and $C_{\max}$ increase proportionally with dose. Steady state is achieved after approximately 15 weeks of treatment. The accumulation ratio of sotatercept AUC was approximately 2.2. Sotatercept exposure in participants with PAH in the phase 3 ZENITH study were consistent with the above data.

Absorption

The subcutaneous (SC) formulation has an absolute bioavailability of approximately 66% based on population pharmacokinetics analysis. The maximum sotatercept concentration is achieved at a median time to peak drug concentration ($T_{\max}$) of approximately 7 days (range from 2 to 8 days) after multiple dosing every 4 weeks.

Distribution

The central volume of distribution (CV%) of sotatercept is approximately 3.6 L (24.7%). The peripheral volume of distribution (CV%) is approximately 1.7 L (73.3%).

Biotransformation

Sotatercept is catabolised by general protein degradation processes.

Elimination

Sotatercept clearance is approximately 0.18 L/day. The geometric mean terminal half-life (CV%) is approximately 21 days (33.8%).

Specific populations

Age, sex, and ethnic origin

No clinically significant differences in sotatercept pharmacokinetics (PK) were observed based on age (18 to 81 years of age), sex, or ethnic origin (82.9% Caucasian, 3.1% Black, 7.1% Asian, and 6.9% other).

Body weight

The clearance and central volume of distribution of sotatercept increase with increasing body weight. The recommended weight-based dosing regimen results in consistent sotatercept exposures.

Renal impairment

Sotatercept pharmacokinetics was comparable in PAH patients with mild to moderate renal impairment (eGFR ranging from 30 to 89 mL/min/1.73m²) to those with normal renal function (eGFR $\geq$ 90 mL/min/1.73m²). Severe renal impairment (eGFR ranging from 15 to 30 mL/min/1.73m², n = 3) had no impact on the PK of sotatercept. Additionally, sotatercept PK is comparable between non-PAH end-stage renal disease (ESRD) patients (eGFR < 15 mL/min/1.73m²) and patients with normal renal function. Sotatercept is not dialyzable during haemodialysis. Limited data are available on the use of sotatercept in PAH patients with severe renal impairment (eGFR < 30 mL/min/1.73m²).

Hepatic impairment

Sotatercept has not been studied in PAH patients with hepatic impairment (Child-Pugh Classification A to C). Hepatic impairment is not expected to influence sotatercept metabolism since sotatercept is metabolised via cellular catabolism.

5.3 Preclinical safety data

No carcinogenicity or mutagenicity studies have been conducted with sotatercept.

Repeat dose toxicity

In rats and monkeys, the longest SC toxicity studies were 3 months and 9 months in duration, respectively. In rats, adverse findings included efferent duct/testicular degeneration, adrenal gland congestion/necrosis, and membranoproliferative glomerulonephritis and tubulointerstitial nephritis in the kidneys. Kidney changes were not reversible following a 1-month recovery period. In monkeys, adverse changes included increased interstitial matrix at the corticomedullary junction, decreased glomerular tuft size, glomerulonephritis and tubulointerstitial nephritis in the kidney. Kidney changes in monkeys partially resolved following a 3-month recovery period. At the no observed adverse effect level (NOAEL) in rats and monkeys, sotatercept exposures were ≤ 2 -times the clinical exposure at the maximum recommended human dose (MRHD). Other findings that occurred at clinical exposure margins in monkeys included hepatic inflammatory infiltrates, lymphoid depletion in spleen, and inflammatory infiltrates in the choroid plexus.

Reproductive toxicity

In a female fertility study, oestrous cycle duration was increased, pregnancy rates were decreased, there were increases in pre-implantation and post-implantation loss and reductions in live litter size. At the NOAEL for female fertility endpoints, sotatercept exposure was 2-times the clinical AUC at the MRHD.

In males, there were non-reversible histologic changes in the efferent ducts, testes, and epididymides. Histomorphologic changes in rat testes correlated to decreased fertility index that reversed during the 13-week treatment-free period. A NOAEL for testicular histologic changes was not established and the NOAEL for male fertility functional changes provides a systemic exposure 2-times the clinical exposure at the MRHD.

In embryo-fetal developmental toxicity studies, effects in rats and rabbits included reductions in numbers of live foetuses and fetal body weights, delays in ossification, and increases in resorptions and post-implantation losses. In rats only, there were also skeletal variations (increased number of supernumerary ribs and changes in the number of thoracic or lumbar vertebrae). At the NOAEL in rats and rabbits, sotatercept exposures were 2-times and 0.4-times, respectively, the clinical exposure at the MRHD.

In a pre- and postnatal development study in rats, no sotatercept related adverse effects were observed in first filial generation (F1) pups from dams dosed during gestation at estimated exposures up to 2-times the MRHD. In F1 pups from dams dosed during lactation, decreases in pup weight correlated with delays in sexual maturation. The NOAEL for effects on growth and maturation in pups provides a systemic exposure 0.6-times the clinical exposure at the MRHD.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Powder

Citric acid monohydrate (E330)
Sodium citrate (E331)
Polysorbate 80 (E433)
Sucrose

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

6.3 Shelf life

Unopened vial

4 years

After reconstitution

Biochemical and biophysical in-use stability has been demonstrated for 4 hours at 30 °C.

From a microbiological point of view, the medicinal product should be used immediately or no longer than 4 hours after reconstitution.

If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.

6.4 Special precautions for storage

Store in a refrigerator (2 °C – 8 °C). Do not freeze.
Store in the original package in order to protect from light.

For storage conditions after reconstitution of the medicinal product, see section 6.3.

6.5 Nature and contents of container

Winrevair 45 mg powder for solution for injection

2 mL capacity, type I glass vial sealed with a bromobutyl rubber stopper with polymer coating and aluminium seal with lime polypropylene flip-off cap containing 45 mg of sotatercept.

Winrevair 60 mg powder for solution for injection

2 mL capacity, type I glass vial sealed with a bromobutyl rubber stopper with polymer coating and aluminium seal with burgundy polypropylene flip-off cap containing 60 mg of sotatercept.

Winrevair powder for solution for injection is available as the following pack sizes:

- Pack containing 1 vial with 45 mg powder
- Pack containing 2 vials with 45 mg powder
- Pack containing 1 vial with 60 mg powder
- Pack containing 2 vials with 60 mg powder

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Selecting the appropriate product pack

If a patient's weight requires the use of two 45 mg or two 60 mg vials, a 2-vial pack should be used

instead of two 1-vial pack to eliminate the need for multiple injections (see section 6.5).

Reconstitution and administration instructions

Winrevair powder for solution for injection should be reconstituted before use and administered as a single injection according to patient weight (see section 4.2).

Reconstitution

- Remove the pack from the refrigerator and wait 15 minutes to allow the medicinal product to come to room temperature prior to preparation.
 - Check the vial to ensure the medicinal product is not expired. The powder should be white to off-white and may look like a whole or broken up cake.
 - Remove the lid from the vial containing the powder and swab the rubber stopper with an alcohol wipe.
 - Reconstitute the content of the vial with sterile water:
 - For each vial of Winrevair 45 mg, inject 1.0 mL of sterile water
 - For each vial of Winrevair 60 mg, inject 1.3 mL of sterile water
- After reconstitution, the 45 mg vial can only provide up to a dose of 0.9 mL of medicinal product and the 60 mg vial can only provide up to a dose of 1.2 mL of medicinal product. The final concentration after reconstitution is 50 mg/mL.
- Gently swirl the vial to reconstitute the medicinal product. Do not shake or vigorously agitate.
 - Allow the vial to stand for up to 3 minutes to allow bubbles to disappear.
 - Visually inspect the reconstituted solution. When properly mixed, the reconstituted solution should be clear to opalescent and colourless to slightly brownish-yellow, and should not have clumps or powder.
 - If prescribed a 2-vial pack, repeat the steps within this section to prepare the second vial.
 - Use the reconstituted solution as soon as possible, but no later than 4 hours after reconstitution.

Administration

Winrevair is to be administered as a single subcutaneous injection.

- Before preparing the dosing syringe, visually inspect the reconstituted solution. The reconstituted solution should be clear to opalescent and colourless to slightly brownish-yellow, and should not have clumps or powder.
- Withdraw the appropriate volume for injection from one or two vials, based on the patient's weight.
- Select the injection site on the abdomen (at least 5 cm away from navel), upper thigh, or upper arm and swab with an alcohol wipe. Select a new site for each injection that is not scarred, tender, or bruised.
- Perform subcutaneous injection.
- Discard the emptied syringe. Do not reuse the syringe.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

See section 4.4 for instructions on the traceability of biological medicinal products.

7. MARKETING AUTHORISATION HOLDER

Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
The Netherlands

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/24/1850/005
EU/1/24/1850/006
EU/1/24/1850/007
EU/1/24/1850/008

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 22 August 2024

10. DATE OF REVISION OF THE TEXT

Detailed information on this medicinal product is available on the website of the European Medicines Agency <https://www.ema.europa.eu>.

ANNEX II

- A. MANUFACTURER OF THE BIOLOGICAL ACTIVE
SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR
BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY
AND USE**
- C. OTHER CONDITIONS AND REQUIREMENTS OF THE
MARKETING AUTHORISATION**
- D. CONDITIONS OR RESTRICTIONS WITH REGARD TO
THE SAFE AND EFFECTIVE USE OF THE MEDICINAL
PRODUCT**

**A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**

Name and address of the manufacturer of the biological active substance

Abbvie Bioresearch Center
100 Research Drive
Worcester, MA 01605
USA

Samsung Biologics Co. Ltd
300 Songdo Bio-Daero,
Yeonsu-Gu, Incheon, 21987,
Republic of Korea

Name and address of the manufacturer responsible for batch release

Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
The Netherlands

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

**C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING
AUTHORISATION**

- **Periodic safety update reports (PSURs)**

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

**D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND
EFFECTIVE USE OF THE MEDICINAL PRODUCT**

- **Risk management plan (RMP)**

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGING – OUTER CARTON**Kit with one 45 mg vial****1. NAME OF THE MEDICINAL PRODUCT**

Winrevair 45 mg powder and solvent for solution for injection
sotatercept

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each vial contains 45 mg of sotatercept. The concentration of the reconstituted solution is 50 mg/mL and 0.9 mL can be withdrawn.

3. LIST OF EXCIPIENTS

Excipients: citric acid monohydrate (E330), sodium citrate (E331), polysorbate 80 (E433), sucrose, water for injections.

4. PHARMACEUTICAL FORM AND CONTENTS

Powder and solvent for solution for injection

1 vial 45 mg (powder), 1 prefilled syringe (solvent), 1 vial adaptor, 1 dosing syringe, 1 needle,
4 alcohol wipes

45 mg

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Subcutaneous use.
Read the package leaflet and booklet before use.
For single use only.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator (2 °C – 8 °C). Do not freeze.
Store in the original package in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/24/1850/001

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY**15. INSTRUCTIONS ON USE****16. INFORMATION IN BRAILLE**

Winrevair 45 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN

19. OTHER – PARTICULARS TO APPEAR ON THE INNER FLAP OF THE CARTON

Top tray


Items in top tray are for mixing the medicine.

A Medicine vial

B Prefilled syringe (solvent)

C Vial adaptor

F Alcohol wipes




Bottom tray

Items in bottom tray are for injecting the medicine.

D Needle

E Dosing syringe for injection

F Alcohol wipes



Important: Do not use Winrevair until your healthcare professional has shown you or your caregiver the right way to prepare and inject this medicine. Please read the **Instructions for Use** before using Winrevair.

MINIMUM PARTICULARS TO APPEAR ON TOP TRAY OF THE CARTON

Kit with one 45 mg vial

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

4. BATCH NUMBER

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

6. OTHER

A

B

C

F

Lift here

MINIMUM PARTICULARS TO APPEAR ON BOTTOM TRAY OF THE CARTON

Kit with one 45 mg vial

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

4. BATCH NUMBER

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

6. OTHER

D

E

F

Lift here

MINIMUM PARTICULARS TO APPEAR ON VIAL LABEL**Kit with one 45 mg vial****1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION**

Winrevair 45 mg powder for injection
sotatercept
SC

2. METHOD OF ADMINISTRATION**3. EXPIRY DATE**

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

45 mg

6. OTHER

MSD

MINIMUM PARTICULARS TO APPEAR ON PREFILLED SYRINGE LABEL

Kit with one 45 mg vial

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Solvent for Winrevair 45 mg

2. METHOD OF ADMINISTRATION**3. EXPIRY DATE**

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

1 mL

6. OTHER

MSD

PARTICULARS TO APPEAR ON THE OUTER PACKAGING – OUTER CARTON

Kit with two 45 mg vials

1. NAME OF THE MEDICINAL PRODUCT

Winrevair 45 mg powder and solvent for solution for injection
sotatercept

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each vial contains 45 mg of sotatercept. The concentration of the reconstituted solution is 50 mg/mL and 1.8 mL can be withdrawn.


3. LIST OF EXCIPIENTS

Excipients: citric acid monohydrate (E330), sodium citrate (E331), polysorbate 80 (E433), sucrose, water for injections.

4. PHARMACEUTICAL FORM AND CONTENTS

Powder and solvent for solution for injection

2 vials 45 mg (powder), 2 prefilled syringes (solvent), 2 vial adaptors, 1 dosing syringe, 1 needle, 8 alcohol wipes



5. METHOD AND ROUTE(S) OF ADMINISTRATION

Subcutaneous use.
Read the package leaflet and booklet before use.
For single use only.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator (2 °C – 8 °C). Do not freeze.
Store in the original package in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/24/1850/002

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY**15. INSTRUCTIONS ON USE****16. INFORMATION IN BRAILLE**

Winrevair 2 x 45 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN

19. OTHER – PARTICULARS TO APPEAR ON THE INNER FLAP OF THE CARTON

Top tray


Items in top tray are for mixing the medicine.

A Medicine vial

B Prefilled syringe (solvent)

C Vial adaptor

F Alcohol wipes




Bottom tray

Items in bottom tray are for injecting the medicine.

D Needle

E Dosing syringe for injection

F Alcohol wipes



Important: Do not use Winrevair until your healthcare professional has shown you or your caregiver the right way to prepare and inject this medicine. Please read the **Instructions for Use** before using Winrevair.

MINIMUM PARTICULARS TO APPEAR ON TOP TRAY OF THE CARTON

Kit with two 45 mg vials

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

4. BATCH NUMBER

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

6. OTHER

Set 1

1/2 A

1/2 B

1/2 C

F

Set 2

2/2 A

2/2 B

2/2 C

Lift here

MINIMUM PARTICULARS TO APPEAR ON BOTTOM TRAY OF THE CARTON

Kit with two 45 mg vials

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

4. BATCH NUMBER

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

6. OTHER

D

E

F

Lift here

MINIMUM PARTICULARS TO APPEAR ON VIAL LABEL**Kit with two 45 mg vials****1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION**

Winrevair 45 mg powder for injection
sotatercept
SC

2. METHOD OF ADMINISTRATION**3. EXPIRY DATE**

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

45 mg

6. OTHER

MSD

MINIMUM PARTICULARS TO APPEAR ON PREFILLED SYRINGE LABEL

Kit with two 45 mg vials

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION
--

Solvent for Winrevair 45 mg

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT
--

1 mL

6. OTHER

MSD

PARTICULARS TO APPEAR ON THE OUTER PACKAGING - OUTER CARTON**Kit with one 60 mg vial****1. NAME OF THE MEDICINAL PRODUCT**

Winrevair 60 mg powder and solvent for solution for injection
sotatercept

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each vial contains 60 mg of sotatercept. The concentration of the reconstituted solution is 50 mg/mL and 1.2 mL can be withdrawn.

3. LIST OF EXCIPIENTS

Excipients: citric acid monohydrate (E330), sodium citrate (E331), polysorbate 80 (E433), sucrose, water for injections.

4. PHARMACEUTICAL FORM AND CONTENTS

Powder and solvent for solution for injection

1 vial **60 mg** (powder), 1 prefilled syringe (solvent), 1 vial adaptor, 1 dosing syringe, 1 needle,
4 alcohol wipes

60 mg

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Subcutaneous use.
Read the package leaflet and booklet before use.
For single use only.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator (2 °C – 8 °C). Do not freeze.
Store in the original package in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/24/1850/003

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY**15. INSTRUCTIONS ON USE****16. INFORMATION IN BRAILLE**

Winrevair 60 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN

19. OTHER – PARTICULARS TO APPEAR ON THE INNER FLAP OF THE CARTON

Top tray


Items in top tray are for mixing the medicine.

A Medicine vial

B Prefilled syringe (solvent)

C Vial adaptor

F Alcohol wipes




Bottom tray

Items in bottom tray are for injecting the medicine.

D Needle

E Dosing syringe for injection

F Alcohol wipes



Important: Do not use Winrevair until your healthcare professional has shown you or your caregiver the right way to prepare and inject this medicine. Please read the **Instructions for Use** before using Winrevair.

MINIMUM PARTICULARS TO APPEAR ON TOP TRAY OF THE CARTON

Kit with one 60 mg vial

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

4. BATCH NUMBER

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

6. OTHER

A

B

C

F

Lift here

MINIMUM PARTICULARS TO APPEAR ON BOTTOM TRAY OF THE CARTON

Kit with one 60 mg vial

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

4. BATCH NUMBER

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

6. OTHER

D

E

F

Lift here

MINIMUM PARTICULARS TO APPEAR ON VIAL LABEL
--

Kit with one 60 mg vial

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION
--

Winrevair 60 mg powder for injection
sotatercept
SC

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT
--

60 mg

6. OTHER

MSD

MINIMUM PARTICULARS TO APPEAR ON PREFILLED SYRINGE LABEL

Kit with one 60 mg vial

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Solvent for Winrevair 60 mg

2. METHOD OF ADMINISTRATION**3. EXPIRY DATE**

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

1.3 mL

6. OTHER

MSD

PARTICULARS TO APPEAR ON THE OUTER PACKAGING - OUTER CARTON

Kit with two 60 mg vials

1. NAME OF THE MEDICINAL PRODUCT

Winrevair 60 mg powder and solvent for solution for injection
sotatercept

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each vial contains 60 mg of sotatercept. The concentration of the reconstituted solution is 50 mg/mL and 2.4 mL can be withdrawn.


3. LIST OF EXCIPIENTS

Excipients: citric acid monohydrate (E330), sodium citrate (E331), polysorbate 80 (E433), sucrose, water for injections.

4. PHARMACEUTICAL FORM AND CONTENTS

Powder and solvent for solution for injection

2 vials **60 mg** (powder), 2 prefilled syringes (solvent), 2 vial adaptors, 1 dosing syringe, 1 needle, 8 alcohol wipes



5. METHOD AND ROUTE(S) OF ADMINISTRATION

Subcutaneous use.
Read the package leaflet and booklet before use.
For single use only.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator (2 °C – 8 °C). Do not freeze.
Store in the original package in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/24/1850/004

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY**15. INSTRUCTIONS ON USE****16. INFORMATION IN BRAILLE**

Winrevair 2 x 60 mg

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN

19. OTHER – PARTICULARS TO APPEAR ON THE INNER FLAP OF THE CARTON

Top tray


Items in top tray are for mixing the medicine.

A Medicine vial

B Prefilled syringe (solvent)

C Vial adaptor

F Alcohol wipes




Bottom tray

Items in bottom tray are for injecting the medicine.

D Needle

E Dosing syringe for injection

F Alcohol wipes



Important: Do not use Winrevair until your healthcare professional has shown you or your caregiver the right way to prepare and inject this medicine. Please read the **Instructions for Use** before using Winrevair.

MINIMUM PARTICULARS TO APPEAR ON TOP TRAY OF THE CARTON

Kit with two 60 mg vials

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

4. BATCH NUMBER

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

6. OTHER

Set 1

1/2 A

1/2 B

1/2 C

F

Set 2

2/2 A

2/2 B

2/2 C

Lift here

MINIMUM PARTICULARS TO APPEAR ON BOTTOM TRAY OF THE CARTON

Kit with two 60 mg vials

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

4. BATCH NUMBER

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

6. OTHER

D

E

F

Lift here

MINIMUM PARTICULARS TO APPEAR ON VIAL LABEL

Kit with two 60 mg vials

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Winrevair 60 mg powder for injection
sotatercept
SC

2. METHOD OF ADMINISTRATION**3. EXPIRY DATE**

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

60 mg

6. OTHER

MSD

MINIMUM PARTICULARS TO APPEAR ON PREFILLED SYRINGE LABEL

Kit with two 60 mg vials

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Solvent for Winrevair 60 mg

2. METHOD OF ADMINISTRATION**3. EXPIRY DATE**

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

1.3 mL

6. OTHER

MSD

PARTICULARS TO APPEAR ON THE OUTER PACKAGING – OUTER CARTON

Pack with one 45 mg vial

1. NAME OF THE MEDICINAL PRODUCT

Winrevair 45 mg powder for solution for injection
sotatercept

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each vial contains 45 mg of sotatercept. The concentration of the reconstituted solution is 50 mg/mL and 0.9 mL can be withdrawn.

3. LIST OF EXCIPIENTS

Excipients: citric acid monohydrate (E330), sodium citrate (E331), polysorbate 80 (E433), sucrose.

4. PHARMACEUTICAL FORM AND CONTENTS

Powder for solution for injection

1 vial 45 mg

45 mg

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Subcutaneous use.
Read the package leaflet before use.
For single use only.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY**8. EXPIRY DATE**

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator (2 °C – 8 °C). Do not freeze.
Store in the original package in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/24/1850/005

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY**15. INSTRUCTIONS ON USE****16. INFORMATION IN BRAILLE**

Justification for not including Braille accepted

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN

MINIMUM PARTICULARS TO APPEAR ON VIAL LABEL

Pack with one 45 mg vial

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Winrevair 45 mg powder for injection
sotatercept
SC

2. METHOD OF ADMINISTRATION**3. EXPIRY DATE**

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

45 mg

6. OTHER

MSD

PARTICULARS TO APPEAR ON THE OUTER PACKAGING – OUTER CARTON

Pack with two 45 mg vials

1. NAME OF THE MEDICINAL PRODUCT

Winrevair 45 mg powder for solution for injection
sotatercept

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each vial contains 45 mg of sotatercept. The concentration of the reconstituted solution is 50 mg/mL and 1.8 mL can be withdrawn.


3. LIST OF EXCIPIENTS

Excipients: citric acid monohydrate (E330), sodium citrate (E331), polysorbate 80 (E433), sucrose.

4. PHARMACEUTICAL FORM AND CONTENTS

Powder for solution for injection

2 vials 45 mg

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Subcutaneous use.
Read the package leaflet before use.
For single use only.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator (2 °C – 8 °C). Do not freeze.
Store in the original package in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/24/1850/006

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY**15. INSTRUCTIONS ON USE****16. INFORMATION IN BRAILLE**

Justification for not including Braille accepted

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN

MINIMUM PARTICULARS TO APPEAR ON VIAL LABEL

Pack with two 45 mg vials

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Winrevair 45 mg powder for injection
sotatercept
SC

2. METHOD OF ADMINISTRATION**3. EXPIRY DATE**

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

45 mg

6. OTHER

MSD

PARTICULARS TO APPEAR ON THE OUTER PACKAGING – OUTER CARTON

Pack with one 60 mg vial

1. NAME OF THE MEDICINAL PRODUCT

Winrevair 60 mg powder for solution for injection
sotatercept

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each vial contains 60 mg of sotatercept. The concentration of the reconstituted solution is 50 mg/mL and 1.2 mL can be withdrawn.

3. LIST OF EXCIPIENTS

Excipients: citric acid monohydrate (E330), sodium citrate (E331), polysorbate 80 (E433), sucrose

4. PHARMACEUTICAL FORM AND CONTENTS

Powder for solution for injection.

1 vial 60 mg

60 mg

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Subcutaneous use.
Read the package leaflet before use.
For single use only.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY**8. EXPIRY DATE**

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator (2 °C – 8 °C). Do not freeze.
Store in the original package in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/24/1850/007

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY**15. INSTRUCTIONS ON USE****16. INFORMATION IN BRAILLE**

Justification for not including Braille accepted

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN

MINIMUM PARTICULARS TO APPEAR ON VIAL LABEL

Pack with one 60 mg vial

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Winrevair 60 mg powder for injection
sotatercept
SC

2. METHOD OF ADMINISTRATION**3. EXPIRY DATE**

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

60 mg

6. OTHER

MSD

PARTICULARS TO APPEAR ON THE OUTER PACKAGING – OUTER CARTON

Pack with two 60 mg vials

1. NAME OF THE MEDICINAL PRODUCT

Winrevair 60 mg powder for solution for injection
sotatercept

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each vial contains 60 mg of sotatercept. The concentration of the reconstituted solution is 50 mg/mL and 2.4 mL can be withdrawn.


3. LIST OF EXCIPIENTS

Excipients: citric acid monohydrate (E330), sodium citrate (E331), polysorbate 80 (E433), sucrose

4. PHARMACEUTICAL FORM AND CONTENTS

Powder for solution for injection.

2 vials 60 mg

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Subcutaneous use.
Read the package leaflet before use.
For single use only.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in a refrigerator (2 °C – 8 °C). Do not freeze.
Store in the original package in order to protect from light.

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
The Netherlands

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/24/1850/008

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY**15. INSTRUCTIONS ON USE****16. INFORMATION IN BRAILLE**

Justification for not including Braille accepted

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC
SN
NN

MINIMUM PARTICULARS TO APPEAR ON VIAL LABEL

Pack with two 60 mg vials

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Winrevair 60 mg powder for injection
sotatercept
SC

2. METHOD OF ADMINISTRATION**3. EXPIRY DATE**

EXP

4. BATCH NUMBER

Lot

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

60 mg

6. OTHER

MSD

B. PACKAGE LEAFLET

Package leaflet: Information for the patient

Winrevair 45 mg powder and solvent for solution for injection **Winrevair 60 mg powder and solvent for solution for injection** sotatercept

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Winrevair is and what it is used for
2. What you need to know before you use Winrevair
3. How to use Winrevair
4. Possible side effects
5. How to store Winrevair
6. Contents of the pack and other information

1. What Winrevair is and what it is used for

Winrevair contains the active substance sotatercept.

It is used with other therapies to treat pulmonary arterial hypertension (PAH) in **adults**. PAH is a type of high blood pressure in the arteries of your lungs. In PAH, these arteries get narrower, which makes it harder for the heart to pump blood through these vessels, and leads to symptoms like fatigue, dizziness, and difficulty breathing.

Winrevair acts on the causes of PAH responsible for the narrowing of the arteries of your lungs, which makes it easier for the heart to pump blood to your lungs and slows down the progression of your disease. It can relieve your symptoms of PAH, help you live longer and lower your need for a lung transplant or hospitalisation for PAH.

2. What you need to know before you use Winrevair

Do not use Winrevair

- if you are allergic to sotatercept or any of the other ingredients of this medicine (listed in section 6).
- If the number of platelets in your blood is repeatedly very low.

Warnings and precautions

Winrevair can increase the levels of haemoglobin in your blood, decrease the number of platelets in your blood, or increase the risk of serious bleeding.

Talk to your doctor or pharmacist before and while using Winrevair if you have:

- **high levels of haemoglobin in your blood** (a protein in red blood cells that carries oxygen).

This can increase the chance of a blood clot forming that can block a blood vessel. Your doctor will check haemoglobin levels with regular blood tests before each of your first 5 doses of Winrevair, or longer before each dose if needed, and regularly while you are using this medicine.

- **low number of platelets in your blood** (blood cells that help blood to clot).
This can cause easy bruising, continued bleeding from cuts and nosebleeds. Your doctor will check your number of platelets with regular blood tests before each of your first 5 doses of Winrevair, or longer before each dose if needed, and regularly while you are using this medicine. In case the number of platelets in your blood is repeatedly very low, your doctor will not start your treatment.
- **signs and symptoms of serious bleeding:**
 - persistent headache
 - nausea
 - weakness
 - black or tarry stool
 - blood in your stool
 - bright red blood from vomiting or coughing
 - persistent abdominal cramps
 - severe back pain
 - abnormally heavy menstrual bleeding

These are signs and symptoms of serious bleeding that can happen if you take Winrevair and are more likely to happen if you take Winrevair with certain medicines. Your doctor will inform you on how to recognize them. Talk to your doctor if you notice any of these signs or symptoms. Serious bleeding could lead to hospitalisation, need for blood transfusion or other treatments, and could be life-threatening.

Children and adolescents

Do not give this medicine to children and adolescents below the age of 18 years. It is not known if this medicine is safe and works in people under 18 years of age.

Other medicines and Winrevair

Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.

Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.

Pregnancy:

Winrevair may harm your unborn baby.

This medicine is not recommended during pregnancy. Your doctor should do a pregnancy test before you start your treatment and you should use effective birth control (contraception) during your treatment and for at least 4 months after the last dose of Winrevair. Ask your doctor or pharmacist about birth control methods that would work well for you.

Tell your doctor immediately if you become pregnant or think you may be pregnant while using this medicine.

Breast-feeding:

It is not known whether Winrevair passes into breast milk. Do not breastfeed during your treatment and for at least 4 months after the last dose of Winrevair. Talk to your doctor or pharmacist about the best way to feed your baby.

Fertility:

Winrevair may decrease female and male fertility.

Driving and using machines

It is unlikely that this medicine will affect your ability to drive and use machines.

Winrevair contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium free’.

Winrevair contains polysorbate 80

This medicine contains 0.20 mg of polysorbate 80 in each mL of reconstituted solution. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergies.

3. How to use Winrevair

Always use this medicine exactly as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist or nurse if you are not sure.

The recommended dosing schedule is one injection every 3 weeks.

Your dose

- Your dose of Winrevair depends on your body weight and blood tests. You will begin your treatment with a dose of 0.3 mg/kg, which will be increased to 0.7 mg/kg.
- Your doctor will tell you how much Winrevair to take and when to take it. It is very important that you follow the instructions from your doctor.
- Do not take Winrevair more often than your doctor tells you to. If you are not sure when to take Winrevair, talk to your doctor or pharmacist.

Your doctor will monitor your dose

- Before each of your first 5 doses, or longer before each dose if needed, and regularly while taking Winrevair, your doctor will do blood tests. This is so your doctor can monitor you and find the best dose for you.
- Your doctor may change your dose, delay treatment, or stop treatment depending on how you respond to Winrevair.

How you will use Winrevair

You will take Winrevair, as an injection just under your skin (subcutaneous (SC)) only in these injection sites:

- **stomach** (abdomen), at least 5 cm away from the belly button, **or**
- **upper thigh**

Note: In case your doctor or nurse is giving you the injection, they may also use your upper arm as injection site as they have received training in how to do it properly.

Before you use Winrevair

- If your doctor decides that you or your caregiver can give the injections of Winrevair at home, you or your caregiver should receive training. This training will teach you the right way to prepare and inject Winrevair. Do not try to inject Winrevair until your doctor has shown you how to do it the right way.
- Your doctor will tell you how much Winrevair to take and when to take it.
- **Read the separate “Instructions for Use” booklet that comes with Winrevair.**

If you use less or more Winrevair than you should

If you use less or more Winrevair than you should, talk to your doctor or pharmacist.

If you forget to use Winrevair

If you miss your prescribed dose of Winrevair and it is within 3 days of when you should have taken it, take it immediately and follow your original schedule for your next dose. If you miss your prescribed dose of Winrevair and it is more than 3 days of when you should have taken it, your injection schedule has to be changed, talk to your doctor or pharmacist for guidance.

If you stop using Winrevair

Do not change your dose or stop taking Winrevair without talking to your doctor.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Serious side effects:

Talk to your doctor or pharmacist **immediately** if you notice:

- Easy bruising, prolonged bleeding from cuts and nosebleeds. These could be signs of a low number of platelets (thrombocytopenia). This will be shown in your blood tests.

In addition, your doctor will do regular blood tests to notice whether you have:

- High levels of haemoglobin.

The serious side effects above may affect more than 1 in 10 people.

Other possible side effects:

Talk to your doctor or pharmacist if you notice any of the following:

Very common (may affect more than 1 in 10 people):

- Headache
- Nosebleeds (epistaxis)
- Spider veins or tiny blood vessels that look like pink or red lines on the skin (telangiectasia)
- Diarrhoea
- Dizziness
- Skin rash
- Bleeding gums
- Back pain
- Bleeding in the digestive system (stomach, intestine, or rectum) that may show as blood in the vomit or in the stool

Common (may affect up to 1 in 10 people):

- High blood pressure
- Redness of the skin
- Lighter or white patches on the skin (skin hypopigmentation)
- Itching at the injection site
- An infection in the urinary tract (kidney, bladder or urethra) that may cause lower back or belly pain and burning during urination
- Fragile or widened blood vessels in the colon (colonic angiodysplasia)

Uncommon (may affect up to 1 in 100 people):

- Intrapulmonary shunting (a condition where blood bypasses the normal route through the lungs that can result in less oxygen delivery to the body)

Not known (frequency cannot be estimated from the available data)

- Build-up of fluid around the heart (pericardial effusion)

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via [the national reporting](#)

system listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Winrevair

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the vial and the carton after “EXP”. The expiry date refers to the last day of that month.

Store in a refrigerator (2 °C – 8 °C). Do not freeze. Store in the original package in order to protect from light.

You should inject this medicine right away after mixing the medicine powder with the sterile water for injection, but no later than 4 hours after mixing.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Winrevair contains

- The active substance is sotatercept. Each vial contains 45 mg or 60 mg of sotatercept. After reconstitution, each mL of solution contains 50 mg of sotatercept.
- The other ingredients are
 - In the powder: citric acid monohydrate (E330), sodium citrate (E331) (see section 2 “Winrevair contains sodium”), polysorbate 80 (E433) (see section 2 “Winrevair contains polysorbate 80”) and sucrose.
 - In the solvent: water for injections.

What Winrevair looks like and contents of the pack

Winrevair is a powder and solvent for solution for injection (powder for injection). The white to off-white powder comes in a 2 mL glass vial containing 45 mg or 60 mg of sotatercept. The solvent is a clear and colourless water for injections in a prefilled syringe of 1 mL or 1.3 mL.

Winrevair 45 mg is available in:

- Pack containing 1 vial 45 mg (powder), 1 prefilled syringe 1.0 mL (solvent), 1 vial adaptor, 1 dosing syringe, 1 needle and 4 alcohol wipes.
- Pack containing 2 vials 45 mg (powder), 2 prefilled syringes 1.0 mL (solvent), 2 vial adaptors, 1 dosing syringe, 1 needle and 8 alcohol wipes.

Winrevair 60 mg is available in:

- Pack containing 1 vial 60 mg (powder), 1 prefilled syringe 1.3 mL (solvent), 1 vial adaptor, 1 dosing syringe, 1 needle and 4 alcohol wipes.
- Pack containing 2 vials 60 mg (powder), 2 prefilled syringes 1.3 mL (solvent), 2 vial adaptors, 1 dosing syringe, 1 needle and 8 alcohol wipes.

Marketing Authorisation Holder and Manufacturer

Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
The Netherlands

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien

MSD Belgium
Tél/Tel: +32(0)27766211
dpoc_belux@msd.com

България

Мерк Шарп и Доум България ЕООД
Тел.: +359 2 819 3737
info-msdbg@msd.com

Česká republika

Merck Sharp & Dohme s.r.o.
Tel.: +420 277 050 000
dpoc_czechslovak@msd.com

Danmark

MSD Danmark ApS
Tlf.: +45 4482 4000
dkmail@msd.com

Deutschland

MSD Sharp & Dohme GmbH
Tel.: +49 (0) 89 20 300 4500
medinfo@msd.de

Eesti

Merck Sharp & Dohme OÜ
Tel: +372 614 4200
dpoc.estonia@msd.com

Ελλάδα

MSD Α.Φ.Ε.Ε.
Τηλ: +30 210 98 97 300
dpoc.greece@msd.com

España

Merck Sharp & Dohme de España, S.A.
Tel: +34 91 321 06 00
msd_info@msd.com

France

MSD France
Tél: +33 (0)1 80 46 40 40

Hrvatska

Merck Sharp & Dohme d.o.o.
Tel: +385 1 6611 333
dpoc.croatia@msd.com

Lietuva

UAB Merck Sharp & Dohme
Tel. +370 5 2780 247
dpoc_lithuania@msd.com

Luxembourg/Luxemburg

MSD Belgium
Tél/Tel: +32(0)27766211
dpoc_belux@msd.com

Magyarország

MSD Pharma Hungary Kft.
Tel.: +36 1 888 5300
hungary_msd@msd.com

Malta

Merck Sharp & Dohme Cyprus Limited
Tel: 8007 4433 (+356 99917558)
dpoccyprus@msd.com

Nederland

Merck Sharp & Dohme B.V.
Tel: 0800 9999000
(+31 23 5153153)
medicalinfo.nl@msd.com

Norge

MSD (Norge) AS
Tlf: +47 32 20 73 00
medinfo.norway@msd.com

Österreich

Merck Sharp & Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 044
dpoc_austria@msd.com

Polska

MSD Polska Sp. z o.o.
Tel.: +48 22 549 51 00
msdpolska@msd.com

Portugal

Merck Sharp & Dohme, Lda
Tel.: +351 21 4465700
inform_pt@msd.com

România

Merck Sharp & Dohme Romania S.R.L.
Tel.: +40 21 529 29 00
msdromania@msd.com

Ireland

Merck Sharp & Dohme Ireland (Human Health) Limited
Tel: +353 (0)1 2998700
medinfo_ireland@msd.com

Ísland

Vistor ehf.
Sími: +354 535 7000

Italia

MSD Italia S.r.l.
Tel: 800 23 99 89 (+39 06 361911)
dpoc.italy@msd.com

Κύπρος

Merck Sharp & Dohme Cyprus Limited
Τηλ: 800 00 673 (+357 22866700)
dpoccyprus@msd.com

Latvija

SIA Merck Sharp & Dohme Latvija
Tel.: +371 67025300
dpoc.latvia@msd.com

Slovenija

Merck Sharp & Dohme, inovativna zdravila d.o.o.
Tel: +386 1 520 4201
msd.slovenia@msd.com

Slovenská republika

Merck Sharp & Dohme, s. r. o.
Tel.: +421 2 58282010
dpoc_czechslovak@msd.com

Suomi/Finland

MSD Finland Oy
Puh/Tel: +358 (0)9 804 650
info@msd.fi

Sverige

Merck Sharp & Dohme (Sweden) AB
Tel: +46 77 5700488
medicinskinfo@msd.com

This leaflet was last revised in {MM/YYYY}.

Detailed information on this medicine is available on the European Medicines Agency web site:
<https://www.ema.europa.eu>.

The following information is intended for healthcare professionals only:

Winrevair powder and solvent for solution for injection should be reconstituted before use and administered as a single injection according to patient weight (see section 4.2 of the Summary of Product Characteristics for recommended dose regimen).

See the separate Instructions for Use booklet provided together with this leaflet for detailed step by step instructions on how to prepare and administer Winrevair powder and solvent for solution for injection. An overview of the reconstitution and administration instructions is provided below.

Reconstitution instructions

- Remove the kit from the refrigerator and wait 15 minutes to allow the prefilled syringe(s) and medicinal product to come to room temperature prior to preparation.
- Check the vial to ensure the medicinal product is not expired. The powder should be white to off-white and may look like a whole or broken up cake.
- Remove the lid from the vial containing the powder and swab the rubber stopper with an alcohol wipe.
- Attach the vial adaptor to the vial.
- Visually inspect the prefilled syringe for any damage or leaks and the sterile water inside to

- ensure there are no visible particles.
- Break off the cap of the prefilled syringe and attach the syringe to the vial adaptor.
- Inject all of the sterile water from the attached syringe into the vial containing the powder:
 - The prefilled syringe provided with the vial 45 mg contains 1.0 mL of sterile water.
 - The prefilled syringe provided with the vial 60 mg contains 1.3 mL of sterile water.
 After reconstitution, the 45 mg vial can only provide up to a dose of 0.9 mL of medicinal product and the 60 mg vial can only provide up to a dose of 1.2 mL of medicinal product. The final concentration after reconstitution is 50 mg/mL.
- Gently swirl the vial to reconstitute the medicinal product. Do not shake or vigorously agitate.
- Allow the vial to stand for up to 3 minutes to allow bubbles to disappear.
- Visually inspect the reconstituted solution. When properly mixed, the reconstituted solution should be clear to opalescent and colourless to slightly brownish-yellow, and should not have clumps or powder.
- Unscrew the syringe from the vial adaptor and discard the emptied syringe.
- If prescribed a 2-vial kit, repeat the steps within this section to prepare the second vial.
- Use the reconstituted solution as soon as possible, but no later than 4 hours after reconstitution.

Dosing syringe preparation

- Before preparing the dosing syringe, visually inspect the reconstituted solution. The reconstituted solution should be clear to opalescent and colourless to slightly brownish-yellow, and should not have clumps or powder.
- Swab the vial adaptor with an alcohol wipe.
- Remove the dosing syringe from its packaging and attach the syringe to the vial adaptor.
- Turn the syringe and vial upside-down and withdraw the appropriate volume for injection, based on the patient's weight.
 - If the dose amount requires the use of two vials, withdraw the entire contents of the first vial and slowly transfer the entire contents into the second vial, to ensure dose accuracy.
 - Turn the syringe and vial upside-down and withdraw the required amount of medicinal product.
- If necessary, push the plunger in to remove excess medicinal product or air from the syringe.
- Remove the syringe from the vial adaptor and attach the needle.

Administration instructions

Winrevair is to be administered as a single SC injection.

- Select the injection site on the abdomen (at least 5 cm away from navel), upper thigh, or upper arm and swab with an alcohol wipe. Select a new site for each injection that is not scarred, tender, or bruised.
 - For administration by the patient or caregiver, train them to inject only in the abdomen or upper thigh (see “**Instructions for Use**” booklet).
- Perform SC injection.
- Discard the emptied syringe. Do not reuse the syringe.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

See section 4.4 of the Summary of Product Characteristics for instructions on the traceability of biological medicinal products.

Instructions for use

Winrevair 45 mg powder and solvent for solution for injection (1 vial - pack) Winrevair 60 mg powder and solvent for solution for injection (1 vial - pack) sotatercept

IMPORTANT: read this booklet before use

Instructions for use

Winrevair 45 mg powder and solvent for solution for injection (1 vial - pack)

Winrevair 60 mg powder and solvent for solution for injection (1 vial - pack)

This booklet contains instructions on how to prepare and inject Winrevair powder and solvent for solution for injection. The package leaflet, also provided in the pack, contains all the important information for you.

Dose based on patient weight

For subcutaneous (SC) injection only (inject directly under the skin)

In this booklet: **(Important)**

Before you start	4
Important information for healthcare professionals	5
Get to know the parts of your pack	6
Important information to know before injecting	8
Storing your pack	9
Get started	10
- Mix powdered medicine into liquid form	12
- Withdraw your prescribed dose	24
- Inject your medicine.....	34
How to throw away Winrevair	36
Frequently asked questions	38

Before you start

Read this booklet

Read these instructions from start to finish before you use Winrevair for the first time and before every administration. There may be new information.

Start with your doctor or nurse

Do not use Winrevair until your doctor or nurse has shown you or your caregiver the right way to prepare and inject it. Your doctor or nurse should show you how to inject Winrevair before you use it for the first time.

Questions?

If you have questions about how to give Winrevair the right way or need more information, talk to your doctor, pharmacist, or nurse.

! Important information for healthcare professionals



A healthcare professional will provide training regarding proper preparation and administration of Winrevair following this “Instructions for Use” (IFU) booklet step-by-step, and decide whether a patient or caregiver is capable of preparing and administering Winrevair independently.

Make sure the patient or caregiver can do the following correctly:



1. Reconstitute the medicine
2. Measure the correct amount of medicine according to patient’s prescription
3. Select and prepare a proper injection site
4. Inject the medicine subcutaneously

Get to know the parts of your pack

Top tray: Use to **mix** the medicine




A 1 Vial of Winrevair medicine powder




C 1 Vial adaptor to connect the vial and syringe

Bottom tray: Use to inject the medicine



D ■ 1 Needle for injection



E ■ 1 Empty dosing syringe to measure, withdraw, and inject your medicine



F ■ 4 Alcohol wipes (2 on each tray)

Important information to know before injecting

- You must mix this product before using it. Make sure the medicine powder in the vial is completely dissolved when you inject it.
- **Check your prescribed dose (amount in ‘mL’) each time you use the product. Your prescribed dose may change.**
- Use only the supplies that are in the pack to prepare your prescribed dose.
- Do not open the pack or mix the medicine until you are ready to use it.
- **Do not reuse any of the supplies.** After your injection, dispose of any unused medicine and used supplies according to local requirements. See pages 36-37 for more information.

Storing your pack

- Store the entire pack in the refrigerator, but do not freeze.
- Keep the medicine and supplies in the pack and away from light.
- Keep pack out of the sight and reach of children and pets.

Get Started

Any patient or caregiver who is to prepare and inject Winrevair must first be trained and deemed capable of independent administration of Winrevair by a healthcare professional.

1 Check Winrevair product and expiry date

Remove the Winrevair pack from the refrigerator.

✓ **Check the expiry date and look for any signs of damage** on the pack or in the supplies.

⚠ If expired or damaged, do not use. Talk to your doctor or pharmacist immediately to get a new pack.

✓ **Check that you have the medicine** that your doctor prescribed.

2 Let your pack come to room temperature, gather supplies, and wash your hands

Wait 15 minutes to allow your pack to warm to room temperature.

Cold medicine is more painful to inject.



15 minutes

Along with your pack, gather these items and find a clean, flat surface where you will prepare and inject your dose.




Sharps
disposal
container




Gauze,
cotton ball
or bandage

Wash your hands with soap and water.




Mix powdered medicine into liquid form (Mix)


Start with the top tray



3 Remove vial, prefilled syringe, and vial adaptor from the pack



4a Check the medicine and the vial




- ✓ Not damaged?
- ✓ No visible particle?
- ✓ Not expired?

Check the vial label to **confirm the medicine is not expired**.

Visually inspect the medicine powder. It should be white to off-white and may look like a whole or broken up cake.

⚠ Do not use if expired, damaged, or you can see particles in it.

4b Remove plastic cap and clean the vial




Flip off the plastic cap and **clean the rubber stopper on top of the vial** with an alcohol wipe.

- ⚠ Do not use if vial cap is missing
- ⚠ Do not touch the cleaned rubber stopper

Set vial aside on a clean, flat surface.


5a Align vial adaptor to vial



Peel open the vial adaptor package and remove it from its package.




To attach the vial adaptor:



Hold the blue neck of the adaptor and align the vial adaptor on top of the vial.

⚠ Do not touch the inside of the vial adaptor to keep it clean and avoid sharps

5b Attach vial adaptor to vial



Hold the vial with one hand. **Push the vial adaptor down firmly** so it snaps in place (you may feel some resistance).


5c Clean vial adaptor



Clean the top of the vial adaptor with an alcohol wipe.

6 Check prefilled syringe


Confirm the product is not expired. Visually inspect that the sterile water inside the prefilled syringe is clear.



⚠ Do not use if you see any clumps, particles, discolouration, or product is expired.

7 Break off prefilled syringe white cap

Break off the prefilled syringe cap along the perforation.



⚠ Do not touch the tip of the prefilled syringe


⚠ Do not push the plunger; it may spill the sterile water

8 Connect prefilled syringe to vial adaptor


Now, pick up the medicine vial with the vial adaptor attached.

Align the prefilled syringe tip on the blue circle of the vial adaptor.

Push and twist the prefilled syringe onto the vial adaptor until you cannot turn further. While twisting, be sure to hold onto the vial adaptor.



9 Transfer sterile water from prefilled syringe to vial




Slowly push the plunger all the way down to transfer all the sterile water into the vial (the plunger will move up; this is normal).

10 Swirl to mix medicine




 Do not shake the vial

Hold the prefilled syringe and ***gently swirl the vial in a circular motion*** until the powder is fully dissolved. This may take up to **2 minutes**. **Do not shake or agitate vigorously.**




When the medicine is mixed well, it should be clear. If not, repeat this step until it is clear.



Press the plunger down again to make sure all the liquid is in the vial since some liquid could have moved back into the syringe (the plunger will move up; this is normal).

11 Wait for the bubbles to go away




Set the vial aside for bubbles to go away.

This may take up to 3 minutes.

- ⚠ Before you continue, make sure the medicine in the vial:
- ✓ Is clear to opalescent and colourless to slightly brownish-yellow.
 - ✓ Does not have clumps or powder.
 - ✓ Does not have large bubbles.

It is okay to have slight foam (small bubbles) around the edges of the vial.


12 Prepare vial by removing extra air



While the vial oriented upright, **gently pull the plunger upwards** to the top of the barrel but be careful not to pull the plunger out of the syringe.


Tip: This step only pulls extra air out of the vial to reduce the pressure in the vial and prevent medicine from spilling during the syringe removal.

13 Remove prefilled syringe from vial



Hold the vial adaptor and unscrew the syringe from the vial.

Throw away the syringe in the sharps container.




You should have a vial of medicine prepared and ready to be used in the next steps.

Withdraw your prescribed dose (Withdraw)


For the next steps, you will need:

- Mixed vial of medicine
- Items from the bottom tray



14 Clean top of vial adaptor


With a new alcohol wipe from the bottom tray, clean the top of the vial adaptor.



15 Remove empty dosing syringe from its package

Find the empty dosing syringe in the bottom tray and remove it from its package.


You will use this dosing syringe to measure out the medicine you need (based on your prescribed dose).



16 Pull air into the dosing syringe


⚠ You must do this to make sure pressure in the vial is even and you get an accurate dose.

Hold the dosing syringe upright and pull down the plunger to **draw air into the dosing syringe**. Stop when you get to the amount in 'mL' listed in your prescription.



17 Connect dosing syringe to the vial


While holding the vial adaptor, screw the dosing syringe on until it stops.



18 Push air into vial, then flip upside down

Push the plunger all the way down to transfer all the air into the vial.


Then **hold the plunger in place** with your thumb and flip the vial upside down.



19 Pull plunger back to withdraw your dose


With the vial and dosing syringe upside down, **slowly pull the plunger back.**

Stop when you get to the **amount in 'mL' listed on your prescription.**



20 Check for air bubbles and air pockets


Check to see if there are large air bubbles or an air pocket in the syringe. You will remove extra air in the next steps.



21 Remove air bubbles and air pockets

If you see air bubbles or an air pocket, tap the side of the dosing syringe to move the air to the top.

Slowly push the plunger up to remove extra air.



22 Compare amount to prescribed dose

After removing all extra air, **compare the amount to your prescribed dose.**


If you do not have your prescribed amount in your syringe, *slowly* pull the plunger back again to withdraw more medicine.



Repeat Steps 19 to 21 until you reach **your prescribed dose** and no large bubbles are visible.

23 Confirm your prescribed dose.


Before you continue, check to make sure you have the prescribed dose in the dosing syringe.



The top rim of the plunger should line up with **your prescribed dose**

⚠ If the amount does not match your prescribed dose, repeat Steps 19 to 22.

24 Remove the dosing syringe from the vial and set the dosing syringe aside




Hold the plunger in place

Throw away used vial

Hold the plunger in place with one hand. With the other hand, hold the vial adaptor and unscrew the filled dosing syringe from the vial.

Throw away the vial into the sharps container.




Place the filled dosing syringe on a clean, flat surface.


⚠ Do not touch the dosing syringe tip or let it touch any surfaces.

25 Attach the injection needle

⚠ Do not touch the connection hub of the needle



Find the needle in the bottom tray and open its package.



With the needle still in the package, **grip the base of the needle** and **twist on the dosing syringe** until it stops. Remove the needle package.




Move the safety shield away from the needle and toward the syringe to the angle shown.

Place the dosing syringe on a clean, flat surface.

⚠ Do not uncap the needle

26 Choose and clean your injection site



Select an injection site on your stomach (abdomen) or your upper thigh. If injecting on your stomach area, avoid a 5 cm area around your belly button.

Choose a different site every time you inject.

⚠ Do not inject into skin that is damaged, sore, bruised, or has red patches

⚠ Do not inject through clothes




Clean the injection site with a new alcohol wipe.

⚠ Do not touch the cleaned injection site again

Now, you are ready to inject the medicine.

Inject your medicine (Inject)


27 Inject your medicine




Pull the cap straight off the needle.

Throw away the cap.

⚠ Do not touch the plunger until ready to inject so you don't lose any medicine




Gently **pinch and hold a fold of skin** where you will inject. Insert the needle with a **dartlike motion at a 45° to 90° angle**. This helps you inject directly under the skin (subcutaneous injection).




Push the plunger with slow, steady pressure all the way down until the dosing syringe is empty.
Confirm all the medicine has been injected.

You can let go of the skin fold now.

⚠ Keep your fingers away from the needle at all times.



While keeping the plunger pushed in, **remove the needle from your skin** at the same angle you inserted it.



To reapply the safety shield, push the shield against a flat surface until you hear a “click” and see that the needle is covered.



Throw away the dosing syringe and used items in a sharps disposal container.

⚠ Do not remove the needle from the dosing syringe

How to throw away Winrevair

Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. Make sure to follow local requirements for disposal as they may be different from the general recommendations below.

- Throw away any used vial (including any remaining Winrevair liquid), needle, vial and needle caps, and used syringes in a sharps disposal container.
- Do not throw away the Winrevair vials, syringes, or needle in your household waste.
- **Do not reuse any of the supplies.** This product is disposable and should only be used one time.
- **Important:** Always keep the sharps disposal container out of reach of children and pets.



If you do not have a sharps disposal container, you may use a household container that is:

- made of a heavy-duty plastic,
- can be closed with a tight-fitting, puncture-resistant lid, without sharp objects being able to come out,
- upright and stable during use,
- leak resistant, and
- properly labelled to warn of hazardous waste inside the container

When your container is almost full, you will need to follow local guidelines for the right way to throw away your container.

 Do not recycle your used container

Frequently asked questions

What should I do if I'm bleeding from the injection site?

Place a cotton ball or bandage on your skin right away and apply a small amount of pressure. If the bleeding does not stop, call your doctor or pharmacist right away.

Where can I find my prescription amount?

Your prescription amount in 'mL' is on your prescription. Contact your doctor or pharmacist if you can't find your prescription amount.

What should I do if I accidentally get some medicine on my skin or my work surface?

Wash the area thoroughly with soap and water right away.

What should I do if I'm not sure I administered my prescribed dose correctly?

Call your doctor or pharmacist.

What should I do if the plunger of my dosing syringe moves automatically when I try to withdraw medicine from the vial?

Don't worry if your plunger moves slightly on its own when you are filling your dosing syringe with medicine.

With one hand, **hold the plunger in place to stop the plunger from moving.**

With the other hand, unscrew the vial from the dosing syringe. Once unscrewed, it is safe to let go of the plunger.

You can avoid this automatic plunger movement by pushing air into the vial before filling your dosing syringe with medicine. Refer to Steps 16 to 23 for detailed instructions.

What should I do if my pack parts are damaged or compromised (for example, discoloured, cloudy, or has particles)?

If your pack parts are damaged or compromised, do not use it. Call your doctor or pharmacist to get a new pack.

What should I do if my medicine does not turn clear after mixing and swirling?

Do not use the medicine if you have swirled the medicine vial for about 2 minutes and let it stand for another 3 minutes, but your medicine vial remains cloudy or has clumps, powder, or foreign particles. Call your doctor or pharmacist to get a new pack.

What should I do if the sterile water won't come out of the prefilled syringe?

Check that the vial adaptor is attached to the vial securely. If not, hold the vial and press the vial adaptor down firmly to make sure the vial adaptor punctures the vial rubber stopper.

What should I do if I dropped my pack components?

Do not use if any items are damaged. If you are unsure, call your doctor or pharmacist to get a new pack.

Can I use my pack that has been left out of the refrigerator?

If the unused pack has been out of the refrigerator for an extended period of time, please contact your doctor or pharmacist before proceeding.

Do I need to use mixed medicine right away?

We recommend you inject the medicine right after mixing but no later than 4 hours after mixing. If it has been more than 4 hours, throw away unused mixed medicine. If you have questions or are unsure about the process, please contact your doctor or pharmacist.

How can I get help preparing and giving my injection?

If you have questions about how to give Winrevair the correct way or need more information, you can call your doctor or pharmacist.

For any other information about this medicine, please contact your doctor or pharmacist, or the local representative of the Marketing Authorisation Holder. You will find the details of the local representative in the Package leaflet: Information for the patient.

This booklet was last revised in MM/YYYY

Instructions for use
Winrevair 45 mg powder and solvent for solution for injection (2 vial – pack)
Winrevair 60 mg powder and solvent for solution for injection (2 vial - pack)
sotatercept

IMPORTANT: read this booklet before use

Instructions for use

Winrevair 45 mg powder and solvent for solution for injection (2 vial - pack)

Winrevair 60 mg powder and solvent for solution for injection (2 vial - pack)

This booklet contains instructions on how to prepare and inject Winrevair powder and solvent for solution for injection. The package leaflet, also provided in the pack, contains all the important information for you.

Dose based on patient weight

For subcutaneous (SC) injection only (inject directly under the skin)

In this booklet: (Important)

Important information for healthcare professionals	3
Before you start	4
Get to know the parts of your pack	6
Important information to know before injecting	8
Storing your pack	9
Get started	10
- Mix powdered medicine into liquid form	12
- Combine medicine from both vials	24
- Withdraw your prescribed dose	30
- Inject your medicine.....	36
How to throw away Winrevair	38
Frequently asked questions	40



Important information for healthcare professionals

A healthcare professional will provide training regarding proper preparation and administration of Winrevair following this “Instructions for Use” (IFU) booklet step-by-step, and decide whether a patient or caregiver is capable of preparing and administering Winrevair independently.

Make sure the patient or caregiver can do the following correctly:

1. Reconstitute the medicine
2. Combine medicine from both vials
3. Measure the correct amount of medicine according to patient’s prescription
4. Select and prepare a proper injection site
5. Inject the medicine subcutaneously

Before you start

Read this booklet

Read these instructions from start to finish before you use Winrevair for the first time and before every administration. There may be new information.

Start with your doctor or nurse

Do not use Winrevair until your doctor or nurse has shown you or your caregiver the right way to prepare and inject it. Your doctor or nurse should show you how to inject Winrevair before you use it for the first time.

Questions?

If you have questions about how to give Winrevair the right way or need more information, talk to your doctor, pharmacist, or nurse.



How to use this product


Before injecting, make sure you read the full instructions in this booklet to get the right dose of medicine.

- **Mix** medicine in vial 1
- **Mix** medicine in vial 2
- **Combine** medicine from both vials
- **Withdraw** your prescribed dose from vial 2
- Then, you’ll be ready to **inject** your medicine

Proceed to the next pages for step-by-step directions.

Get to know the parts of your pack

Top tray: Use to **mix** the medicine




Vial —
Medicine powder

A — 2 Vials of Winrevair
medicine powder




B — 2 Prefilled syringes (solvent) with
sterile water to mix medicine
powder into liquid




C — 2 Vial adaptors
to connect the vial
and syringe

Bottom tray: Use to **inject** the medicine



D ■ 1 Needle for injection



E ■ 1 Empty dosing syringe
to measure, withdraw, and inject your medicine



F ■ 8 Alcohol wipes
(4 on each tray)

Important information to know before injecting

- You must mix this product before using it. Make sure the medicine powder in the vial is completely dissolved when you inject
- **Check your prescribed dose (amount in ‘mL’) each time you use the product. Your prescribed dose may change.**
- Use only the supplies that are in the pack to prepare your prescribed dose.
- Do not open the pack or mix the medicine until you are ready to use it.
- **Do not reuse any of the supplies.** After your injection, dispose of any unused medicine and used supplies according to the local requirements. See pages 38-39 for more information.

Storing your pack

- Store the entire pack in the refrigerator, but do not freeze.
- Keep the medicine and supplies in the pack and away from light.
- Keep pack out of the sight and reach of children and pets.

Get Started

Any patient or caregiver who is to prepare and inject Winrevair must first be trained and deemed capable of independent administration of Winrevair by a healthcare professional.

1 Check Winrevair product and expiry date

Remove the Winrevair pack from the refrigerator.

✓ **Check the expiry date and look for any signs of damage** on the pack or in the supplies.

⚠ If expired or damaged, do not use. Talk to your doctor or pharmacist immediately to get a new pack.

✓ **Check that you have the medicine** that your doctor prescribed.

2 Let your pack come to room temperature, gather supplies, and wash your hands

Wait 15 minutes to allow your pack to warm to room temperature.

Cold medicine is more painful to inject.



15 minutes

Along with your pack, gather these items and find a clean, flat surface where you will prepare and inject your dose.




Sharps
disposal
container




Gauze,
cotton ball
or bandage

Wash your hands with soap and water.




Mix powdered medicine into liquid form (Mix)


Start with the top tray



3 Remove vial 1, prefilled syringe 1, and vial adaptor 1 from the pack



4a Check the medicine and the vial




- ✓ Not damaged?
- ✓ No visible particle?
- ✓ Not expired?

Check the vial label to **confirm the medicine is not expired.**

Visually inspect the medicine powder. It should be white to off-white and may look like a whole or broken up cake.

⚠ Do not use if expired, damaged, or you can see particles in it

4b Remove plastic cap and clean the vial




Flip off the plastic cap and **clean the rubber stopper on top of the vial** with an alcohol wipe.

- ⚠ Do not use if vial cap is missing
- ⚠ Do not touch the cleaned rubber stopper

Set vial aside on a clean, flat surface.


5a Align vial adaptor to vial



Peel open the vial adaptor package and remove it from its package.




To attach the vial adaptor:



Hold the blue neck of the adaptor and align the vial adaptor on top of the vial.


⚠ Do not touch the inside of the vial adaptor to keep it clean and avoid sharps

5b Attach vial adaptor to vial



Hold the vial with one hand. **Push the vial adaptor down firmly** so it snaps in place (you may feel some resistance).


5c Clean vial adaptor



Clean the top of the vial adaptor with an alcohol wipe.

6 Check prefilled syringe


Confirm the product is not expired. Visually inspect that the sterile water inside the prefilled syringe is clear.



⚠ Do not use if you see any clumps, particles, discolouration, or product is expired

7 Break off prefilled syringe white cap

Break off the prefilled syringe cap along the perforation.



⚠ Do not touch the tip of the prefilled syringe


⚠ Do not push the plunger; it may spill the sterile water

8 Connect prefilled syringe to vial adaptor


Now, pick up the medicine vial with the vial adaptor attached.

Align the prefilled syringe tip on the blue circle of the vial adaptor.

Push and twist the prefilled syringe onto the vial adaptor until you cannot turn further. While twisting, be sure to hold onto the vial adaptor.



9 Transfer sterile water from prefilled syringe to vial



Slowly push the plunger all the way down to transfer all the sterile water into the vial (the plunger will move up; this is normal).


Leave the prefilled syringe attached to the vial and set aside on a flat surface.

10 Prepare vial 2, prefilled syringe 2, and vial adaptor 2

Remove **vial 2, prefilled syringe 2, and vial adaptor 2** from the pack.

⚠ Important:

Turn back to page 13 and repeat Steps 4 to 9 to prepare vial 2.




Vial 1 Vial 2

Stop and check if you have both vial 1 and vial 2 prepared.


You need both vials prepared before you can continue to Step 11.

11 Swirl to mix medicine




⚠ Do not shake the vials

Hold one prefilled syringe in each hand and ***gently swirl both vials in a circular motion*** until the powder is fully dissolved. This may take up to **2 minutes**. **Do not shake or agitate vigorously.**




When the medicine is mixed well, it should be clear. If not, repeat this step until it is clear.



For each vial, **press the plunger down** again to make sure all the liquid is in the vial since some liquid could have moved back into the syringe (the plunger will move up; this is normal).

12 Wait for the bubbles to go away




Set both vials aside for bubbles to go away.
This may take up to 3 minutes.

- ⚠ Before you continue, make sure the medicine in the vial:
- ✓ Is clear to opalescent and colourless to slightly brownish-yellow
 - ✓ Does not have clumps or powder
 - ✓ Does not have large bubbles

It is okay to have slight foam (small bubbles) around the edges of the vial

13 Prepare vial by removing extra air




Start with either vial. While having the vial oriented upright, **gently pull the plunger upwards** to the top of the barrel but be careful not to pull the plunger out of the syringe.


Tip: This step only pulls extra air out of the vial to reduce the pressure in the vial and prevent medicine from spilling during the syringe removal.

Important:

⚠ Perform this step for **both** vials. Stop and check you have **both** vials prepared before continuing.




14 Remove prefilled syringe from vial



Hold the vial adaptors and unscrew **both** syringes from the vials.

Throw away **both** syringes in the sharps container.




You should have 2 vials of medicine prepared and ready to be combined in the next steps.

Combine medicine from both vials (Combine)

For the next steps, you will need:

- Mixed vial 1 and vial 2
- Items from the bottom tray



15 Clean top of both vial adaptors


With 2 new alcohol wipes from the bottom tray, clean the top of the vial adaptors.



16 Remove empty dosing syringe from its package

Find the empty dosing syringe in the bottom tray and remove it from its package.


You will use this dosing syringe to measure out the medicine you need (based on your prescribed dose).



17 Pull air into the dosing syringe

⚠ You must do this to make sure pressure in the vial is even and you get an accurate dose.

Hold the dosing syringe upright and pull down the plunger to **draw in 1.5 mL of air**.




Top rim of the plunger

Pull plunger until top rim of plunger is at 1.5 mL

Tip: Each line on the dosing syringe is 0.1 mL.

18 Connect dosing syringe to one of the vials


While holding the vial adaptor, screw the dosing syringe on until it stops.



19 Push air into vial, then flip upside down

Push the plunger all the way down to transfer all the air into the vial.

Then **hold the plunger in place** with your thumb and flip the vial upside down.



20 Drain all the medicine from 1st vial

Slowly pull the plunger back. **Stop at 1.5 mL.**

This will make sure all the medicine in the vial is in the dosing syringe.


- ⚠ Do not pull the plunger beyond 1.5 mL. **Stop at 1.5 mL**
- ⚠ Be careful not to pull the plunger out of the dosing syringe



21 Remove 1st vial from the dosing syringe

Hold the vial adaptor and unscrew the filled dosing syringe from the vial.


Throw away the **empty** vial into the sharps container.



22 Connect the dosing syringe to the 2nd vial

While holding the vial adaptor of the 2nd vial, screw the partially filled dosing syringe onto the vial adaptor until it stops.


⚠ Do not touch the plunger; it may spill medicine



23 Push all the medicine into the 2nd vial, then flip upside down

Slowly push the plunger all the way down to transfer **all of the medicine into the vial** to ensure dose accuracy. This combines the medicine from both vials.

Then **hold the plunger in place** with your thumb and flip the vial upside down.




Withdraw your prescribed dose (Withdraw)

24 Pull plunger back to withdraw your dose


With the vial and dosing syringe upside down, **slowly pull the plunger back**.

Stop when you get to the **amount in 'mL' listed on your prescription**.



25 Check for air bubbles and air pockets


Check to see if there are large air bubbles or an air pocket in the syringe. You will remove extra air in the next steps.



26 Remove air bubbles and air pockets

If you see air bubbles or an air pocket, tap the side of the dosing syringe to move the air to the top.

Slowly push the plunger up to remove extra air.



27 Compare amount to prescribed dose

After removing all extra air, **compare the amount to your prescribed dose.**


If you do not have your prescribed amount in your syringe, *slowly* pull the plunger back again to withdraw more medicine.



Repeat Steps 24 to 26 until you reach **your prescribed dose** and no large bubbles are visible.

28 Confirm your prescribed dose


Before you continue, check to make sure you have the prescribed dose in the dosing syringe.



The top rim of the plunger should line up with **your prescribed dose**

⚠ If the amount does not match your prescribed dose, repeat Steps 24 to 27.

29 Remove the dosing syringe from the vial and set the dosing syringe aside



Hold the plunger in place with one hand. With the other hand, hold the vial adaptor and unscrew the filled dosing syringe from the vial.

Throw away the vial into the sharps container.




Place the filled dosing syringe on a clean, flat surface.


⚠ Do not touch the dosing syringe tip or let it touch any surfaces.

30 Attach the injection needle


⚠ Do not touch the connection hub of the needle



Find the needle in the bottom tray and open its package.




With the needle still in the package, **grip the base of the needle** and **twist on the dosing syringe** until it stops. Remove the needle package.



Move the safety shield away from the needle and toward the syringe to the angle shown.
Place the dosing syringe on a clean, flat surface.

⚠ Do not uncap the needle

31 Choose and clean your injection site



Select an injection site on your stomach (abdomen) or your upper thigh. If injecting on your stomach area, avoid a 5 cm area around your belly button.

Choose a different site every time you inject.

⚠ Do not inject into skin that is damaged, sore, bruised, or has red patches

⚠ Do not inject through clothes




Clean the injection site with a new alcohol wipe.

⚠ Do not touch the cleaned injection site again

Now, you are ready to inject the medicine.

Inject your medicine


32 Inject your medicine (Inject)




Pull the cap straight off the needle.

Throw away the cap.

⚠ Do not touch the plunger until ready to inject so you don't lose any medicine




Gently **pinch and hold a fold of skin** where you will inject. Insert the needle with a **dartlike motion at a 45° to 90° angle**. This helps you inject directly under the skin (subcutaneous injection).




Push the plunger with slow, steady pressure all the way down until the dosing syringe is empty.
Confirm all the medicine has been injected.
 You can let go of the skin fold now.

⚠ Keep your fingers away from the needle at all times.



While keeping the plunger pushed in, **remove the needle from your skin** at the same angle you inserted it.



To reapply the safety shield, push the shield against a flat surface until you hear a “click” and see that the needle is covered.



Throw away the dosing syringe and used items in a sharps disposal container.

⚠ Do not remove the needle from the dosing syringe

How to throw away Winrevair

Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. Make sure to follow local requirements for disposal as they may be different from the general recommendations below:

- Throw away any used vial (including any remaining Winrevair liquid), needle, vial and needle caps, and used syringes in a sharps disposal container.
- Do not throw away the Winrevair vials, syringes, or needle in your household waste.
- **Do not reuse any of the supplies.** This product is disposable and should only be used one time.
- **Important:** Always keep the sharps disposal container out of reach of children and pets.



If you do not have a sharps disposal container, you may use a household container that is:

- made of a heavy-duty plastic,
- can be closed with a tight-fitting, puncture-resistant lid, without sharp objects being able to come out,
- upright and stable during use,
- leak resistant, and
- properly labelled to warn of hazardous waste inside the container

When your container is almost full, you will need to follow local guidelines for the right way to throw away your container.

 Do not recycle your used container

Frequently asked questions

What should I do if I'm bleeding from the injection site?

Place a cotton ball or bandage on your skin right away and apply a small amount of pressure. If the bleeding does not stop, call your doctor or pharmacist right away.

Where can I find my prescription amount?

Your prescription amount in 'mL' is on your prescription. Contact your doctor or pharmacist if you can't find your prescription amount.

What should I do if I accidentally get some medicine on my skin or my work surface?

Wash the area thoroughly with soap and water right away.

What should I do if I'm not sure I administered my prescribed dose correctly?

Call your doctor or pharmacist.

What should I do if the plunger of my dosing syringe moves automatically when I try to withdraw medicine from the vial?

Don't worry if your plunger moves slightly on its own when you are filling your dosing syringe with medicine.

With one hand, **hold the plunger in place to stop the plunger from moving.**

With the other hand, unscrew the vial from the dosing syringe. Once unscrewed, it is safe to let go of the plunger.

You can avoid this automatic plunger movement by pushing air into the vial before filling your dosing syringe with medicine. Refer to Steps 17 to 28 for detailed instructions.

What should I do if my pack parts are damaged or compromised (for example, discoloured, cloudy, or has particles)?

If your pack parts are damaged or compromised, do not use it. Call your doctor or pharmacist to get a new pack.

What should I do if my medicine does not turn clear after mixing and swirling?

Do not use the medicine if you have swirled the medicine vial for about 2 minutes and let it stand for another 3 minutes, but your medicine vial remains cloudy or has clumps, powder, or foreign particles. Call your doctor or pharmacist to get a new pack.

What should I do if the sterile water won't come out of the prefilled syringe?

Check that the vial adaptor is attached to the vial securely. If not, hold the vial and press the vial adaptor down firmly to make sure the vial adaptor punctures the vial rubber stopper.

What should I do if I dropped my pack components?

Do not use if any items are damaged. If you are unsure, call your doctor or pharmacist to get a new pack.

Can I use my pack that has been left out of the refrigerator?

If the unused pack has been out of the refrigerator for an extended period of time, please contact your doctor or pharmacist before proceeding.

Do I need to use mixed medicine right away?

We recommend you inject the medicine right after mixing but no later than 4 hours after mixing. If it has been more than 4 hours, throw away unused mixed medicine. If you have questions or are unsure about the process, please contact your doctor or pharmacist.

How can I get help preparing and giving my injection?

If you have questions about how to give Winrevair the correct way or need more information, you can call your doctor or pharmacist.

For any other information about this medicine, please contact your doctor or pharmacist, or the local representative of the Marketing Authorisation Holder. You will find the details of the local representative in the Package leaflet: Information for the patient.

This booklet was last revised in MM/YYYY

Package leaflet: Information for the patient

Winrevair 45 mg powder for solution for injection

Winrevair 60 mg powder for solution for injection

sotatercept

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Winrevair is and what it is used for
2. What you need to know before you use Winrevair
3. How you are given Winrevair
4. Possible side effects
5. How to store Winrevair
6. Contents of the pack and other information

1. What Winrevair is and what it is used for

Winrevair contains the active substance sotatercept.

It is used with other therapies to treat pulmonary arterial hypertension (PAH) in **adults**. PAH is a type of high blood pressure in the arteries of your lungs. In PAH, these arteries get narrower, which makes it harder for the heart to pump blood through these vessels, and leads to symptoms like fatigue, dizziness, and difficulty breathing.

Winrevair acts on the causes of PAH responsible for the narrowing of the arteries of your lungs, which makes it easier for the heart to pump blood to your lungs and slows down the progression of your disease. It can relieve your symptoms of PAH, help you live longer and lower your need for a lung transplant or hospitalisation for PAH.

2. What you need to know before you use Winrevair

Do not use Winrevair

- if you are allergic to sotatercept or any of the other ingredients of this medicine (listed in section 6).
- If the number of platelets in your blood is repeatedly very low.

Warnings and precautions

Winrevair can increase the levels of haemoglobin in your blood, decrease the number of platelets in your blood, or increase the risk of serious bleeding.

Talk to your doctor or pharmacist before and while using Winrevair if you have:

- **high levels of haemoglobin in your blood** (a protein in red blood cells that carries oxygen).

This can increase the chance of a blood clot forming that can block a blood vessel. Your doctor will check haemoglobin levels with regular blood tests before each of your first 5 doses of Winrevair, or longer before each dose if needed, and regularly while you are using this medicine.

- **low number of platelets in your blood** (blood cells that help blood to clot).
This can cause easy bruising, continued bleeding from cuts and nosebleeds. Your doctor will check your number of platelets with regular blood tests before each of your first 5 doses of Winrevair, or longer before each dose if needed, and regularly while you are using this medicine. In case the number of platelets in your blood is repeatedly very low, your doctor will not start your treatment.
- **signs and symptoms of serious bleeding:**
 - persistent headache
 - nausea
 - weakness
 - black or tarry stool
 - blood in your stool
 - bright red blood from vomiting or coughing
 - persistent abdominal cramps
 - severe back pain
 - abnormally heavy menstrual bleeding

These are signs and symptoms of serious bleeding that can happen if you take Winrevair and are more likely to happen if you take Winrevair with certain medicines. Your doctor will inform you on how to recognize them. Talk to your doctor if you notice any of these signs or symptoms. Serious bleeding could lead to hospitalisation, need for blood transfusion or other treatments, and could be life-threatening.

Children and adolescents

Do not give this medicine to children and adolescents below the age of 18 years. It is not known if this medicine is safe and works in people under 18 years of age.

Other medicines and Winrevair

Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.

Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.

Pregnancy:

Winrevair may harm your unborn baby.

This medicine is not recommended during pregnancy. Your doctor should do a pregnancy test before you start your treatment and you should use effective birth control (contraception) during your treatment and for at least 4 months after the last dose of Winrevair. Ask your doctor or pharmacist about birth control methods that would work well for you.

Tell your doctor immediately if you become pregnant or think you may be pregnant while using this medicine.

Breast-feeding:

It is not known whether Winrevair passes into breast milk. Do not breastfeed during your treatment and for at least 4 months after the last dose of Winrevair. Talk to your doctor or pharmacist about the best way to feed your baby.

Fertility:

Winrevair may decrease female and male fertility.

Driving and using machines

It is unlikely that this medicine will affect your ability to drive and use machines.

Winrevair contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium free’.

Winrevair contains polysorbate 80

This medicine contains 0.20 mg of polysorbate 80 in each mL of reconstituted solution. Polysorbates may cause allergic reactions. Tell your doctor if you have any known allergies.

3. How you are given Winrevair

The recommended dosing schedule is one injection every 3 weeks.

Your doctor will monitor your dose

- Your dose of Winrevair depends on your body weight and blood tests. You will be given a first dose of 0.3 mg/kg, then your dose will be increased to 0.7 mg/kg.
- Before each of your first 5 doses, or longer before each dose if needed, and regularly while taking Winrevair, your doctor will do blood tests. This is so your doctor can monitor you and find the best dose for you.
- Your doctor may change your dose, delay treatment, or stop treatment depending on how you respond to Winrevair.

How you are given Winrevair

You will be given Winrevair, as an injection just under your skin (subcutaneous (SC)) only in these injection sites:

- **stomach** (abdomen), at least 5 cm away from the belly button, **or**
- **upper thigh, or**
- **upper arm**

If you are given more Winrevair than you should

As this product is given by a doctor or other healthcare professional, it is very unlikely that you will be given an incorrect dose of Winrevair. However, if you have any concerns you should let your doctor, pharmacist or nurse know immediately.

If you miss your appointment to be given Winrevair

If you miss your appointment to be given Winrevair, call your doctor immediately to reschedule your appointment.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Serious side effects:

Talk to your doctor or pharmacist **immediately** if you notice:

- Easy bruising, prolonged bleeding from cuts and nosebleeds. These could be signs of a low number of platelets (thrombocytopenia). This will be shown in your blood tests.

In addition, your doctor will do regular blood tests to notice whether you have:

- High levels of haemoglobin.

The serious side effects above may affect more than 1 in 10 people.

Other possible side effects:

Talk to your doctor or pharmacist if you notice any of the following:

Very common (may affect more than 1 in 10 people):

- Headache
- Nosebleeds (epistaxis)
- Spider veins or tiny blood vessels that look like pink or red lines on the skin (telangiectasia)
- Diarrhoea
- Dizziness
- Skin rash
- Bleeding gums
- Back pain
- Bleeding in the digestive system (stomach, intestine, or rectum) that may show as blood in the vomit or in the stool

Common (may affect up to 1 in 10 people):

- High blood pressure
- Redness of the skin
- Lighter or white patches on the skin (skin hypopigmentation)
- Itching at the injection site
- An infection in the urinary tract (kidney, bladder or urethra) that may cause lower back or belly pain and burning during urination
- Fragile or widened blood vessels in the colon (colonic angiodysplasia)

Uncommon (may affect up to 1 in 100 people):

- Intrapulmonary shunting (a condition where blood bypasses the normal route through the lungs that can result in less oxygen delivery to the body)

Not known (frequency cannot be estimated from the available data)

- Build-up of fluid around the heart (pericardial effusion)

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Winrevair

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the vial and the carton after “EXP”. The expiry date refers to the last day of that month.

Store in a refrigerator (2 °C – 8 °C). Do not freeze. Store in the original package in order to protect from light.

After reconstitution (mixing of the powder with sterile water), use this medicine immediately or no longer than 4 hours after reconstitution.

Do not throw away any medicines via wastewater. Any unused medicinal product or waste material including material used for reconstitution and administration should be disposed of in accordance with local requirements. These measures will help protect the environment.

6. Contents of the pack and other information

What Winrevair contains

- The active substance is sotatercept. Each vial contains 45 mg or 60 mg of sotatercept. After reconstitution, each mL of solution contains 50 mg of sotatercept.
- The other ingredients are citric acid monohydrate (E330), sodium citrate (E331) (see section 2 “Winrevair contains sodium”), polysorbate 80 (E433) (see section 2 “Winrevair contains polysorbate 80”) and sucrose.

What Winrevair looks like and contents of the pack

Winrevair is a powder for solution for injection (powder for injection). The white to off-white powder comes in a 2 mL glass vial containing 45 mg or 60 mg of sotatercept.

Winrevair 45 mg is available in:

- Pack containing 1 vial with 45 mg powder
- Pack containing 2 vials with 45 mg powder

Winrevair 60 mg is available in:

- Pack containing 1 vial 60 mg powder
- Pack containing 2 vials 60 mg powder

Marketing Authorisation Holder and Manufacturer

Merck Sharp & Dohme B.V.

Waarderweg 39

2031 BN Haarlem

The Netherlands

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

België/Belgique/Belgien

MSD Belgium

Tél/Tel: +32(0)27766211

dpoc_belux@msd.com

Lietuva

UAB Merck Sharp & Dohme

Tel. +370 5 2780 247

dpoc_lithuania@msd.com

България

Мерк Шарп и Доум България ЕООД

Тел.: +359 2 819 3737

info-msdbg@msd.com

Luxembourg/Luxemburg

MSD Belgium

Tél/Tel: +32(0)27766211

dpoc_belux@msd.com

Česká republika

Merck Sharp & Dohme s.r.o.

Tel.: +420 277 050 000

dpoc_czechslovak@msd.com

Magyarország

MSD Pharma Hungary Kft.

Tel.: +36 1 888 5300

hungary_msd@msd.com

Danmark

MSD Danmark ApS

Tlf.: +45 4482 4000

dkmail@msd.com

Malta

Merck Sharp & Dohme Cyprus Limited

Tel: 8007 4433 (+356 99917558)

dpoccyprus@msd.com

Deutschland

MSD Sharp & Dohme GmbH
Tel.: +49 (0) 89 20 300 4500
medinfo@msd.de

Eesti

Merck Sharp & Dohme OÜ
Tel: +372 614 4200
dpoc.estonia@msd.com

Ελλάδα

MSD A.Φ.E.E.
Τηλ: +30 210 98 97 300
dpoc.greece@msd.com

España

Merck Sharp & Dohme de España, S.A.
Tel: +34 91 321 06 00
msd_info@msd.com

France

MSD France
Tél: +33 (0)1 80 46 40 40

Hrvatska

Merck Sharp & Dohme d.o.o.
Tel: +385 1 6611 333
dpoc.croatia@msd.com

Ireland

Merck Sharp & Dohme Ireland (Human Health) Limited
Tel: +353 (0)1 2998700
medinfo_ireland@msd.com

Ísland

Vistor ehf.
Sími: +354 535 7000

Italia

MSD Italia S.r.l.
Tel: 800 23 99 89 (+39 06 361911)
dpoc.italy@msd.com

Κύπρος

Merck Sharp & Dohme Cyprus Limited
Τηλ: 800 00 673 (+357 22866700)
dpoccyprus@msd.com

Latvija

SIA Merck Sharp & Dohme Latvija
Tel.: +371 67025300
dpoc.latvia@msd.com

Nederland

Merck Sharp & Dohme B.V.
Tel: 0800 9999000
(+31 23 5153153)
medicalinfo.nl@msd.com

Norge

MSD (Norge) AS
Tlf: +47 32 20 73 00
medinfo.norway@msd.com

Österreich

Merck Sharp & Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 044
dpoc_austria@msd.com

Polska

MSD Polska Sp. z o.o.
Tel.: +48 22 549 51 00
msdpolska@msd.com

Portugal

Merck Sharp & Dohme, Lda
Tel.: +351 21 4465700
inform_pt@msd.com

România

Merck Sharp & Dohme Romania S.R.L.
Tel.: +40 21 529 29 00
msdromania@msd.com

Slovenija

Merck Sharp & Dohme, inovativna zdravila d.o.o.
Tel: +386 1 520 4201
msd.slovenia@msd.com

Slovenská republika

Merck Sharp & Dohme, s. r. o.
Tel.: +421 2 58282010
dpoc_czechslovak@msd.com

Suomi/Finland

MSD Finland Oy
Puh/Tel: +358 (0)9 804 650
info@msd.fi

Sverige

Merck Sharp & Dohme (Sweden) AB
Tel: +46 77 5700488
medicinskinfo@msd.com

This leaflet was last revised in {MM/YYYY}.

Detailed information on this medicine is available on the European Medicines Agency web site:
<https://www.ema.europa.eu>.

The following information is intended for healthcare professionals only:

Winrevair powder for solution for injection should be reconstituted before use and administered as a single injection according to patient weight (see section 4.2 of the Summary of Product Characteristics for reconstitution and administration instructions).

Reconstitution instructions

- Remove the pack from the refrigerator and wait 15 minutes to allow the medicinal product to come to room temperature prior to preparation.
- Check the vial to ensure the medicinal product is not expired. The powder should be white to off-white and may look like a whole or broken up cake.
- Remove the lid from the vial containing the powder and swab the rubber stopper with an alcohol wipe.
- Reconstitute the content of the vial with sterile water:
 - For each vial of Winrevair 45 mg, inject 1.0 mL of sterile water
 - For each vial of Winrevair 60 mg, inject 1.3 mL of sterile waterAfter reconstitution, the 45 mg vial can only provide up to a dose of 0.9 mL of medicinal product and the 60 mg vial can only provide up to a dose of 1.2 mL of medicinal product. The final concentration after reconstitution is 50 mg/mL.
- Gently swirl the vial to reconstitute the medicinal product. Do not shake or vigorously agitate.
- Allow the vial to stand for up to 3 minutes to allow bubbles to disappear.
- Visually inspect the reconstituted solution. When properly mixed, the reconstituted solution should be clear to opalescent and colourless to slightly brownish-yellow, and should not have clumps or powder.
- If prescribed a 2-vial pack, repeat the steps within this section to prepare the second vial.
- Use the reconstituted solution as soon as possible, but no later than 4 hours after reconstitution.

Administration instructions

Winrevair is to be administered as a single subcutaneous injection.

- Before preparing the dosing syringe, visually inspect the reconstituted solution. The reconstituted solution should be clear to opalescent and colourless to slightly brownish-yellow, and should not have clumps or powder.
- Withdraw the appropriate volume for injection from one or two vials, based on the patient's weight.
- Select the injection site on the abdomen (at least 5 cm away from navel), upper thigh, or upper arm and swab with an alcohol wipe. Select a new site for each injection that is not scarred, tender, or bruised.
- Perform subcutaneous injection.
- Discard the emptied syringe. Do not reuse the syringe.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

See section 4.4 of the Summary of Product Characteristics for instructions on the traceability of biological medicinal products.